# Rewrite chunk 003 — entries 101-150

_Previous: rewrite-PHONE-002.md | Next: rewrite-PHONE-004.md | Index: rewrite-PHONE-INDEX.md_

Edit ONLY the `YOUR REWRITE` section under each entry. The `Original`
block is frozen — do not edit it. Save the file when done. On your
laptop run `python C:\E156\merge-rewrite.py` to assemble a new
workbook (`rewrite-workbook.NEW.txt`) with your edits applied.

---

## Entry 101 ([103/921]) — MetaRep

<details><summary>Metadata</summary>

```
TITLE: MetaRep: Most Significant Cochrane Meta-Analyses Predict Only 32% Replication Probability When Heterogeneity Is Accounted For
TYPE: methods  |  ESTIMAND: Replication probability (heterogeneity-aware predictive power)
DATA: Pairwise70 dataset: 398 Cochrane reviews, 183 with significant effects
PATH: C:\Models\MetaRep
```

</details>

### Original (frozen — do not edit)

```
What is the probability that a new clinical trial will replicate a significant Cochrane meta-analysis conclusion when between-study heterogeneity is properly accounted for? We analysed 398 Cochrane meta-analyses from the Pairwise70 dataset using restricted maximum likelihood estimation, focusing on 183 reviews with statistically significant pooled effects. MetaRep computes replication probability from the predictive distribution of a new study, incorporating both sampling error and between-study variance tau-squared into a single heterogeneity-aware power formula. Among significant meta-analyses, the median replication probability was 31.8 percent (IQR 16.0 to 63.6 percent), with 65.6 percent having replication probability below 50 percent. The primary driver was between-study heterogeneity rather than inadequate sample size, with median I-squared of 26.1 percent. Even meta-analyses deemed definitive by conventional standards predict roughly a one-in-three chance that the next appropriately sized trial will produce a significant confirmatory result. These estimates may not generalise beyond Cochrane reviews and are limited by the assumption of normally distributed between-study heterogeneity.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Can a new clinical trial replicate a significant Cochrane meta-analysis conclusion when between-study heterogeneity is properly accounted for? We used 398 Cochrane meta-analyses from the Pairwise70 dataset using restricted maximum likelihood estimation, this focused on 183 reviews with statistically significant pooled effects; metaRep computes replication probability from the predictive distribution of a new study. It incorporates both sampling error and between-study variance tau-squared into a single heterogeneity-aware power formula. Among significant meta-analyses, the median replication probability was 31.8 percent (IQR 16.0 to 63.6 percent); 65.6 percent has replication probability below 50 percent. The primary driver was between-study heterogeneity rather than inadequate sample size, with median I-squared of 26.1 percent. Meta-analyses deemed definitive by conventional standards predict roughly a one-in-three chance that the next appropriately sized trial will produce a significant confirmatory result. These estimates may not generalise beyond Cochrane reviews.
<!-- END-REWRITE -->

_Line range 7668-7742 in rewrite-workbook.txt_

---

## Entry 102 ([104/921]) — MetaRepair

<details><summary>Metadata</summary>

```
TITLE: MetaRepair: Automated Diagnosis and Correction of Meta-Analysis Pathologies
TYPE: empirical  |  ESTIMAND: Corrected pooled effect with uncertainty decomposition
DATA: 403 Cochrane reviews from Pairwise70 dataset
PATH: C:\Models\MetaRepair
```

</details>

### Original (frozen — do not edit)

```
Can automated diagnosis and correction of meta-analytic pathologies produce uncertainty estimates decomposing variance into its constituent sources? We applied a four-stage pipeline to 403 Cochrane reviews: multimodality diagnosis via Gaussian mixture BIC comparison, outlier detection through studentized residuals, bias assessment using Egger regression and trim-and-fill, and stability testing across eight specifications combining four estimators with two CI methods. Corrections include Winsorized pooling for outliers, PET-PEESE for bias, and subgroup splitting for multimodal distributions, with five-component decomposition separating sampling, heterogeneity, model, bias, and outlier contributions. Across 403 reviews, the median OR shift after correction was 1.12 with 95% CI 1.05 to 1.21, and 68 percent exhibited at least one pathology. Uncertainty decomposition revealed heterogeneity contributed a median 47 percent of total variance, exceeding sampling uncertainty in most reviews. MetaRepair provides systematic diagnostic-then-correct workflow producing graded estimates with transparent uncertainty attribution. The limitation is that automated correction cannot replace judgment about whether pathologies reflect biological heterogeneity versus artifacts.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Can automated diagnosis and correction of meta-analytic pathologies create better uncertainty estimates than naive pooling? We applied a four-stage pipeline to 403 Cochrane reviews: multimodality diagnosis via Gaussian mixture models, outlier detection through Cook's distance, publication bias correction using PET-PEESE, and uncertainty decomposition. Corrections include Winsorized pooling for outliers, PET-PEESE for bias, and subgroup splitting for multimodality, each with graded confidence labels. In 403 reviews, the median OR shift after correction was 1.12 with 95% CI 1.05 to 1.21, and 68 percent showed at least one actionable pathology. Uncertainty decomposition revealed heterogeneity contributed a median 47 percent of total variance. MetaRepair provides a systematic diagnostic-then-correct workflow producing graded estimates with decomposed uncertainty. Automated correction cannot replace judgment about whether pathologies reflect true clinical diversity or methodological artifacts.
<!-- END-REWRITE -->

_Line range 7743-7817 in rewrite-workbook.txt_

---

## Entry 103 ([106/921]) — MetaReproducer

<details><summary>Metadata</summary>

```
TITLE: Computational Reproducibility Audit of 501 Cochrane Meta-Analyses
TYPE: methods  |  ESTIMAND: Prevalence
DATA: 501 Cochrane systematic reviews, 14,340 studies, Pairwise70 dataset
PATH: C:\Models\MetaReproducer
```

</details>

### Original (frozen — do not edit)

```
Can Cochrane meta-analyses be computationally reproduced when an automated pipeline re-extracts effect sizes from source trial publications? We audited 501 Cochrane systematic reviews encompassing 14,340 individual studies using MetaReproducer, a deterministic pipeline that parses RevMan data files, retrieves open-access PDFs, extracts effects via RCT Extractor v10.3, and re-pools results using inverse-variance random-effects models. The pipeline infers effect type by back-computing candidate log-odds and log-risk ratios from two-by-two tables, matching against Cochrane reference values within 0.0001 tolerance on the log scale. Only 1,688 of 14,340 studies had accessible PDFs, yielding an open-access prevalence of 11.8 percent (95% CI 11.3-12.3), leaving most evidence computationally unverifiable. Among six reviews with sufficient coverage for classification, two showed major discrepancies including one complete direction change. The primary barrier to reproducibility is infrastructural access rather than methodology, suggesting that mandating structured data deposition could transform verification. This fundamental limitation of open-access coverage constrains any automated reproducibility audit of the published evidence base.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Can Cochrane meta-analyses be computationally reproduced when an automated pipeline re-extracts effect sizes from the available source trial publications? We audited 501 Cochrane systematic reviews encompassing 14,340 individual studies. We used MetaReproducer, a deterministic pipeline that parses RevMan data files, retrieves open-access PDFs, extracts effects via RCT Extractor v10.3, It re-pools results using inverse-variance random-effects models. The pipeline infers effect type by back-computing candidate log-odds and log-risk ratios from two-by-two tables - matching against Cochrane reference values within 0.0001 tolerance on the log scale. Only 1,688 of 14,340 studies had accessible PDFs, yielding an open-access prevalence of 11.8 percent (95% CI 11.3-12.3). This left most evidence computationally unverifiable, among six reviews with sufficient coverage for classification, two showed major discrepancies (including one complete direction change). The primary barrier to reproducibility is infrastructural access rather than methodology.This suggests that mandating structured data deposition could transform verification, this fundamental limitation of open-access coverage constrains any automated reproducibility audits.
<!-- END-REWRITE -->

_Line range 7818-7892 in rewrite-workbook.txt_

---

## Entry 104 ([107/921]) — MetaShift

<details><summary>Metadata</summary>

```
TITLE: MetaShift: Changepoint Detection Reveals Hidden Regime Shifts in Cumulative Meta-Analysis
TYPE: methods  |  ESTIMAND: Changepoint detection rate
DATA: Pairwise70 dataset (10 reviews with trajectories, 393 aggregate)
PATH: C:\MetaShift
```

</details>

### Original (frozen — do not edit)

```
At what point during the accumulation of primary studies does a cumulative meta-analysis pooled estimate undergo detectable trajectory shifts? We built cumulative DerSimonian-Laird random-effects meta-analyses for ten Cochrane reviews with per-study data from Pairwise70, plus aggregate summaries for 393 additional reviews. Three changepoint algorithms were applied: CUSUM charts for mean shifts, PELT segmentation for variance changes, and a significance-flip detector tracking p-value crossings. Of ten fully traced reviews, the median number of changepoints was two (95% CI 1-4), seven exhibited heterogeneity spikes, and only two stabilized before the accumulation midpoint. CUSUM and PELT agreed on spike location in six of seven cases, and higher final heterogeneity predicted late instability across the full 403-review corpus. Changepoint methods reveal that most cumulative meta-analyses undergo detectable regime shifts that standard forest plots obscure from readers and guideline developers. However, this approach is limited to chronological ordering and cannot account for selective reporting of interim cumulative results by review authors.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
During the accumulation of primary studies does a cumulative meta-analysis pooled estimate undergo detectable trajectory shifts? We built cumulative DerSimonian-Laird random-effects meta-analyses for ten real Cochrane reviews with per-study data from Pairwise70, this also gives aggregate summaries for 393 additional reviews. Three changepoint algorithms were tried: CUSUM charts for mean shifts, PELT segmentation for variance changes, and a significance-flip detector tracking p-value crossings. In the ten fully traced reviews, the median number of changepoints was two (95% CI 1-4), seven exhibited heterogeneity spikes, and only two stabilized before the accumulation midpoint. CUSUM and PELT also agreed on spike location in six of seven cases, the higher final heterogeneity predicted late instability across the full 403-review corpus. Changepoint methods reveal that most cumulative meta-analyses undergo detectable regime shifts that standard forest plots obscure from readers and guideline developers. However, this approach is limited to chronological ordering.
<!-- END-REWRITE -->

_Line range 7893-7967 in rewrite-workbook.txt_

---

## Entry 105 ([108/921]) — metasprint-autopilot

<details><summary>Metadata</summary>

```
TITLE: MetaSprint Autopilot: Zero-Install Browser Platform for Systematic Review and Meta-Analysis
TYPE: methods  |  ESTIMAND: Engine accuracy vs Cochrane reviews
DATA: 291 Cochrane reviews (triple-blinded validation)
PATH: C:\Projects\metasprint-autopilot
```

</details>

### Original (frozen — do not edit)

```
Can a zero-install browser application match the statistical accuracy of validated meta-analysis software across hundreds of Cochrane reviews? MetaSprint Autopilot is a single HTML file implementing a complete seven-phase systematic review workflow from topic discovery through manuscript drafting, validated against 291 Cochrane reviews via triple-blinded architecture. The engine provides DerSimonian-Laird, REML, Mantel-Haenszel, and Peto pooling with Hartung-Knapp-Sidik-Jonkman intervals, publication bias diagnostics, living meta-analysis with sequential stopping rules, and GRADE assessment. Across all 291 reviews the engine achieved 100.0 percent accuracy with median effect difference of 1.65 times ten to the negative seventh, and R metafor v4.8.0 cross-validation confirmed exact agreement with concordance coefficient of 1.0000. Leave-one-out analysis showed 24.9 percent of reviews changed direction upon single-study removal, and 92.2 percent of prediction intervals crossed the null. The platform eliminates software installation barriers while preserving statistical rigor for global evidence synthesis. However, a limitation is that open-access search discovery rates remain moderate at 58 to 65 percent.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Will a zero-install browser application match the statistical accuracy of validated meta-analysis software across Cochrane reviews? MetaSprint Autopilot is a single HTML file implementing a complete seven-phase systematic review workflow from topic discovery through manuscript drafting, validated against 291 Cochrane reviews via triple-blinded architecture. The engine provides DerSimonian-Laird, REML, Mantel-Haenszel, and Peto pooling with Hartung-Knapp-Sidik-Jonkman intervals, publication bias diagnostics, living meta-analysis with sequential stopping rules, and GRADE assessment. In all 291 reviews the engine achieved 100.0 percent accuracy with median effect difference of 1.65 times ten to the negative seventh. The R metafor v4.8.0 cross-validation confirmed exact agreement with concordance coefficient of 1.0000. A Leave-one-out analysis showed 24.9 percent of reviews changed direction upon single-study removal, and 92.2 percent of prediction intervals crossed the null. This platform eliminates software installation barriers while preserving statistical rigor for global evidence synthesis, a limitation is that open-access search discovery rates remain moderate at 58 to 65 percent.
<!-- END-REWRITE -->

_Line range 7968-8042 in rewrite-workbook.txt_

---

## Entry 106 ([109/921]) — metasprint-cardio-universe

<details><summary>Metadata</summary>

```
TITLE: MetaSprint Cardio Universe: Provenance-First Discovery for Living Evidence Synthesis
TYPE: methods  |  ESTIMAND: Ingestion recall
DATA: 6 source connectors (CT.gov, AACT, PubMed, OpenAlex, Europe PMC)
PATH: C:\Projects\metasprint-cardio-universe
```

</details>

### Original (frozen — do not edit)

```
Can a provenance-first discovery platform map the cardiovascular trial universe from heterogeneous registries into a unified ontology for living systematic reviews? We built a Node.js engine ingesting records from ClinicalTrials.gov, AACT, PubMed, OpenAlex, and Europe PMC, performing identity deduplication with human-reviewable overrides and mapping interventions to a cardiology ontology. The platform implements REML and HKSJ pairwise statistics, network meta-analysis with inconsistency diagnostics, risk-of-bias integration, and living-update drift monitoring with scenario-tuned stability thresholds. Across six connectors, ingestion sensitivity exceeded 95 percent for expected NCT identifiers, with deduplication precision of 92 percent (95% CI 88 to 95) against manually curated gold-standard pairs. Blinded expert review across two independent cycles confirmed editorial readiness scoring above the Lancet quality threshold for completeness and accuracy. The discovery shell provides six interactive visualizations including network graphs, gap scatter plots, timeline views, and evidence maps with filtering. However, a limitation is that registry completeness varies by geography, potentially underrepresenting trials from low-resource settings.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Will a provenance-first discovery platform map the cardiovascular trial universe from heterogeneous registries into a unified ontology for living systematic reviews? We built a Node.js engine for ingesting records from ClinicalTrials.gov, AACT, PubMed, OpenAlex, and Europe PMC, performing identity deduplication with human-reviewable overrides and mapping interventions (to a cardiology ontology). The platform implements REML and HKSJ pairwise statistics, network meta-analysis with inconsistency diagnostics, risk-of-bias integration, and living-update drift monitoring with scenario-tuned stability thresholds. Across six connectors the ingestion sensitivity exceeded 95 percent for expected NCT identifiers. The deduplication precision was 92 percent (95% CI 88 to 95) against manually curated gold-standard pairs. The discovery shell also provides six interactive visualizations including network graphs, gap scatter plots, timeline views, and evidence maps with filtering. A limitation is that registry completeness varies by geography.
<!-- END-REWRITE -->

_Line range 8043-8117 in rewrite-workbook.txt_

---

## Entry 107 ([110/921]) — metasprint-dose-response

<details><summary>Metadata</summary>

```
TITLE: MetaSprint Dose-Response: Browser-Based Nonlinear Dose-Response Meta-Analysis with R Cross-Validation
TYPE: methods  |  ESTIMAND: Dose-response coefficients
DATA: R dosresmeta2 v2.2.0 reference datasets (alcohol_cvd, coffee_mort)
PATH: C:\Projects\metasprint-dose-response
```

</details>

### Original (frozen — do not edit)

```
Can a browser-based application implement dose-response meta-analysis with nonlinear models validated against established R packages without requiring installation? MetaSprint Dose-Response is a single HTML file of 25,800 lines implementing eight dose-response models including linear, quadratic, Emax, fractional polynomial, and restricted cubic splines with Greenland-Longnecker covariance reconstruction for correlated dose contrasts. The engine provides ML and REML estimation via profile likelihood with golden-section optimization, one-stage mixed-effects modeling, AIC-weighted model averaging across fitted curves, and Bayesian Laplace approximation with credible interval bands. Cross-validation against R dosresmeta2 v2.2.0 confirmed agreement within tolerance of 1e-4 for coefficients, standard errors, tau-squared, AIC, and predictions across linear, quadratic, and spline models. Leave-one-out sensitivity analysis across six studies and bootstrap breakpoint confidence intervals with 500 cluster resamples provide robustness assessment for dose-finding decisions. The platform delivers publication-quality dose-response curves directly from a structured 40-day sprint workflow. However, a limitation is that the current implementation supports only two-level study-dose clustering without three-level hierarchical extensions.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Will a browser-based application implement dose-response meta-analysis with nonlinear models validated against R dosresmeta2? MetaSprint Dose-Response is a single HTML file implementing eight dose-response models including linear, quadratic, restricted cubic splines, fractional polynomials, Emax, sigmoid Emax, piecewise linear, and log-linear specifications. The engine provides ML and REML estimation via profile likelihood with golden-section optimization, alongside model comparison through AIC and BIC with automated best-model selection. Cross-validation against R dosresmeta2 v2.2.0 confirmed agreement within tolerance of 1e-4 for coefficient estimates, standard errors, and goodness-of-fit statistics across all eight model families. Leave-one-out sensitivity analysis across six studies and bootstrap breakpoint confidence intervals both demonstrated stability of the identified dose thresholds. Browser-based dose-response modeling enables point-of-care exploration of nonlinear treatment effects without programming. The tool assumes monotonic or unimodal dose-response shapes and cannot model discontinuous threshold effects.
<!-- END-REWRITE -->

_Line range 8118-8192 in rewrite-workbook.txt_

---

## Entry 108 ([111/921]) — metasprint-dta

<details><summary>Metadata</summary>

```
TITLE: MetaSprint DTA: Automated Open-Access Discovery for Diagnostic Test Accuracy Meta-Analysis
TYPE: methods  |  ESTIMAND: Pooled sensitivity and specificity
DATA: 70 published DTA meta-analyses across 13 specialties
PATH: C:\Projects\metasprint-dta
```

</details>

### Original (frozen — do not edit)

```
Can automated extraction from open-access abstracts produce pooled diagnostic accuracy estimates consistent with published meta-analyses across diverse specialties? MetaSprint DTA integrates a four-source discovery pipeline searching ClinicalTrials.gov, Europe PMC, OpenAlex, and PubMed with a bivariate GLMM and HSROC engine in a single browser application requiring no installation. The pipeline extracts sensitivity, specificity, and sample sizes using over 30 regex patterns with Unicode preprocessing, back-calculates two-by-two tables, and pools estimates within one session. Across 70 published DTA meta-analyses spanning 13 specialties, all pooled estimates fell within 15 percent of published values with study counts frequently exceeding published reviews, and R cross-validation achieved 33 of 33 parity against mada and metafor. Advanced diagnostics include Cook distance, DFBETAS, Copas selection model, profile-likelihood confidence intervals, and bootstrap BCa intervals. The platform bridges the months-long gap between clinical question and pooled diagnostic accuracy estimate. However, a limitation is that abstract-only extraction cannot capture studies reporting accuracy metrics solely in full-text tables.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Will automated extraction from open-access abstracts produce pooled diagnostic accuracy estimates consistent with published meta-analyses ? MetaSprint DTA integrates a four-source discovery pipeline searching ClinicalTrials.gov, Europe PMC, OpenAlex, and PubMed, it uses a bivariate GLMM and HSROC engine in a single browser application. The pipeline then extracts sensitivity, specificity, and sample sizes using over 30 regex patterns with Unicode preprocessing, it back-calculates two-by-two tables and pools estimates within one session. Across 70 published DTA meta-analyses spanning 13 specialties, all pooled estimates fell within 15 percent of published values. Study counts frequently exceeded published reviews; r cross-validation achieved 33 of 33 parity against mada and metafor. Advanced diagnostics include Cook distance, DFBETAS, Copas selection model, profile-likelihood confidence intervals, and bootstrap BCa intervals, the platform bridges the long gap between clinical question and pooled diagnostic accuracy estimates. A limitation is that abstract-only extraction cannot capture studies reporting accuracy metrics in full-text tables.
<!-- END-REWRITE -->

_Line range 8193-8267 in rewrite-workbook.txt_

---

## Entry 109 ([112/921]) — metasprintnma

<details><summary>Metadata</summary>

```
TITLE: MetaSprint NMA: Zero-Install Browser Network Meta-Analysis with In-Browser R Cross-Validation
TYPE: methods  |  ESTIMAND: Treatment effect concordance
DATA: 70 clinical topics across 10 therapeutic areas
PATH: C:\Projects\metasprintnma
```

</details>

### Original (frozen — do not edit)

```
Can a zero-install browser application provide clinician-accessible network meta-analysis with built-in R cross-validation for every single computed result? MetaSprint NMA is a single HTML file of 31,500 lines implementing frequentist and Bayesian network meta-analysis with 70 pre-loaded clinical topics spanning 10 therapeutic areas including oncology, cardiology, and nephrology. The application implements the graph-theoretic approach with DerSimonian-Laird, REML, and Paule-Mandel heterogeneity estimation, Bayesian MCMC via Metropolis-Hastings, P-score ranking, node-splitting inconsistency detection, net heat plots, and CINeMA GRADE assessment. Feature comparison showed 23 of 23 assessed capabilities versus 11 of 23 for netmeta and MetaInsight, and all 70 topics produced concordance-verified results against published trial estimates with WebR in-browser validation. Gold-standard regression testing against three canonical datasets confirmed tau-squared, treatment effects, and ranking agreement within all documented tolerances. The platform makes publication-quality NMA accessible to clinicians who lack programming skills. However, a limitation is that WebR validation requires an initial internet connection to load the 20-megabyte R runtime.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Will a zero-install browser application provide clinician-accessible network meta-analysis with built-in R cross-validation? MetaSprint NMA is a single HTML file implementing frequentist and Bayesian network meta-analysis, it has 70 pre-loaded clinical topics spanning 10 therapeutic areas including oncology, cardiology, and nephrology. The application implements the graph-theoretic approach with DerSimonian-Laird, REML, and Paule-Mandel heterogeneity estimation, Bayesian MCMC via Metropolis-Hastings, P-score ranking, node-splitting inconsistency detection, net heat plots, and CINeMA GRADE assessment. A comparison showed 23 of 23 assessed capabilities versus 11 of 23 for netmeta and MetaInsight, all 70 topics produced concordance-verified results against published trial estimates with WebR in-browser validation. The Gold-standard regression testing against three canonical datasets confirmed tau-squared, treatment effects, and ranking agreement within all documented tolerances. This platform makes publication-quality NMA accessible to clinicians who lack programming skills. The limitation is that WebR validation requires an initial internet connection to load the 20-megabyte R runtime.
<!-- END-REWRITE -->

_Line range 8268-8342 in rewrite-workbook.txt_

---

## Entry 110 ([113/921]) — metaverse-robust-MA

<details><summary>Metadata</summary>

```
TITLE: metaverse: Robust Meta-Analysis with Outlier-Resistant Estimation and Variable Selection
TYPE: methods  |  ESTIMAND: Pooled SMD bias
DATA: Simulated 60-study dataset with 10% contamination
PATH: C:\Projects\metaverse-robust-MA
```

</details>

### Original (frozen — do not edit)

```
Can robust estimation methods protect meta-analytic conclusions from outlier contamination while maintaining valid inference under standard conditions? We developed the metaverse R package implementing M, MM, S, and tau-scale estimators with contamination models alongside knockoff filters, spike-and-slab selection, penalized regression, conformal prediction, and post-selection inference for moderators. The package provides 12 plot types including forest, funnel, radial, and influence diagnostics, plus effect-size converters covering 10 metrics and power analysis for study planning. Under 10 percent contamination across 60 studies the pooled SMD bias was 0.02 (95% CI 0.00 to 0.04) for the MM-estimator versus 0.15 for standard DerSimonian-Laird estimation. Knockoff-filtered variable selection maintained FDR below the nominal 10 percent threshold while correctly detecting both true moderators in the evaluation dataset. The framework integrates with metafor workflows and supports dependent effect sizes through multilevel modeling via the lme4 package. A limitation is that robust estimators require approximately 20 studies to reliably outperform standard methods under low contamination.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Will robust estimation methods protect meta-analytic conclusions from outlier contamination under standard conditions? We have developed the metaverse R package implementing M, MM, S, and tau-scale estimators with contamination models, this has knockoff filters, spike-and-slab selection, penalized regression, conformal prediction, and post-selection inference for moderators. This package provides 12 plot types including forest, funnel, radial, and influence diagnostics, it has effect-size converters covering 10 metrics and power analysis for study planning. Under 10 percent contamination across 60 studies the pooled SMD bias was 0.02 (95% CI 0.00 to 0.04) for the MM-estimator versus 0.15 for standard DerSimonian-Laird estimation. Knockoff-filtered variable selection maintained FDR below the nominal 10 percent threshold, it also correctly detected both true moderators in the evaluation dataset, the framework integrates with metafor workflows. It supports dependent effect sizes through multilevel modeling via the lme4 package. A limitation is that robust estimators require approximately 20 studies to reliably outperform standard methods under low contamination.
<!-- END-REWRITE -->

_Line range 8343-8417 in rewrite-workbook.txt_

---

## Entry 111 ([114/921]) — MethodsSuite

<details><summary>Metadata</summary>

```
TITLE: Methods Suite: Eight Interoperable Browser-Based Meta-Analysis Tools with MAIF
TYPE: methods  |  ESTIMAND: Cross-tool MAIF round-trip fidelity
DATA: 8 tools, 200 Selenium tests, R-validated
PATH: C:\Models\MethodsSuite
```

</details>

### Original (frozen — do not edit)

```
Can eight interoperable browser-based meta-analysis tools connected by a common JSON interchange format deliver complete evidence synthesis without server dependency? The Suite comprises PRISMA Checker, RoB Assessor, MA Power, Pooling Suite, PubBias Suite, Meta-Regression, Bayesian MA, and Component NMA, each validated with 25 Selenium tests and cross-checked against R packages including metafor, bayesmeta, and netmeta. The Meta-Analysis Interchange Format requires study identifiers with effect estimates and standard errors, with each tool additively enriching the dataset by appending domain-specific results to shared JSON. All 200 tests pass with median OR deviation from R below 0.001 and 95% CI coverage matching nominal rates across pairs. Prior sensitivity in Bayesian MA and permutation testing in Meta-Regression produce results within 2 percent of R benchmarks. This suite demonstrates modular browser tools with standardized interchange can replace fragmented desktop workflows for meta-analysis. The limitation is that MAIF currently supports only univariate effects and cannot represent multivariate or network data without extension.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Can eight interoperable browser-based meta-analysis tools connected through a common JSON interchange format deliver complete evidence synthesis without server dependency? Thus comprises PRISMA Checker, RoB Assessor, MA Power, Pooling Suite, PubBias Suite, Meta-Regression, Bayesian MA, and Component NMA, (each validated with 25 Selenium tests and cross-checked against R packages including metafor, bayesmeta, and netmeta). The Meta-Analysis Interchange Format requires study identifiers with effect estimates and standard errors, each tool additively enriches the dataset by appending domain-specific results to shared JSON. All 200 tests pass with median OR deviation from R below 0.001 with 95% CI coverage matching nominal rates across pairs. Prior sensitivity in Bayesian MA and permutation testing in Meta-Regression produced results within 2 percent of R benchmarks. This suite shows that modular browser tools with standardized interchange can replace fragmented desktop workflows for meta-analysis. The limitation is that MAIF currently supports only univariate effects.
<!-- END-REWRITE -->

_Line range 8418-8492 in rewrite-workbook.txt_

---

## Entry 112 ([115/921]) — MLM501

<details><summary>Metadata</summary>

```
TITLE: MLM501: A Multilevel Effects Table from 501 Cochrane Pairwise Meta-Analysis Reviews
TYPE: data  |  ESTIMAND: Median effects per analysis (IQR)
DATA: 501 Cochrane pairwise review datasets (27,998 effect sizes, 375 reviews)
PATH: C:\Projects\MLM501
```

</details>

### Original (frozen — do not edit)

```
What is the scope of dependent effect sizes across a comprehensive corpus of Cochrane pairwise meta-analyses? We imported 501 Cochrane systematic review datasets and constructed a unified multilevel effects table containing 27,998 rows spanning 375 reviews, 5,951 analyses, and 4,854 studies across dichotomous, continuous, and generic summary outcomes. The MLM501 R package provides read-only importers, coherent cohort subsetting by outcome and measure, and visualization for effect size distributions across review hierarchies. The median number of effect sizes per analysis was 3 (IQR 2 to 6), confirming substantial within-analysis dependence requiring multilevel modeling in 68 percent of analyses with median I-squared of 41 percent. Meta-meta-analysis pooling summaries with random intercepts by review reproduced published heterogeneity patterns across dichotomous and continuous cohorts. This database provides the first large-scale empirical foundation for stress-testing multilevel meta-analysis methods on real Cochrane data. The dataset scope is limited to a single extraction snapshot and cannot capture subsequent review updates or protocol amendments.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
What would be dependent effect sizes across a comprehensive corpus of Cochrane pairwise meta-analyses? We imported 501 Cochrane systematic review datasets to constructed a unified multilevel effects table containing 27,998 rows spanning 375 reviews, 5,951 analyses, and 4,854 studies across dichotomous, continuous, and generic summary outcomes. The MLM501 R package gives read-only importers, coherent cohort subsetting by outcome and measure, and visualization for effect size distributions across review hierarchies. The median number of effect sizes per analysis was 3 (IQR 2 to 6). This confirms substantial within-analysis dependence requiring multilevel modeling in 68 percent of analyses with median I-squared of 41 percent. Meta-meta-analysis pooling summaries with random intercepts by review reproduced published heterogeneity patterns across dichotomous and continuous cohorts. This database provides a large-scale empirical foundation for stress-testing multilevel meta-analysis methods on real Cochrane data, the dataset scope is limited to a single extraction snapshot.
<!-- END-REWRITE -->

_Line range 8493-8567 in rewrite-workbook.txt_

---

## Entry 113 ([116/921]) — MLMResearch

<details><summary>Metadata</summary>

```
TITLE: MLMResearch: Empirical Stress-Testing and Adaptive Correction for Multilevel Meta-Analysis Methods
TYPE: methods  |  ESTIMAND: Variance collapse rate with median degrees of freedom (IQR)
DATA: 501 Cochrane review datasets via MLM501; REML + RVE method comparison
PATH: C:\Projects\MLMResearch
```

</details>

### Original (frozen — do not edit)

```
How frequently do standard multilevel meta-analysis methods fail on real-world Cochrane data rather than idealized simulations? We developed MLMResearch, an R companion to MLM501, providing evaluation of restricted maximum likelihood and robust variance estimation across 501 Cochrane datasets with automated detection of convergence failures, variance collapse, and small-sample bias. The package implements adaptive robust variance estimation selecting optimal corrections based on cluster count, applying CR2 Satterthwaite adjustments when clusters fall below 40. Diagnostics revealed variance collapse in 42 percent of three-level REML models with median degrees of freedom of 8.4 (IQR 5.2 to 12.1), while 78 percent had insufficient clusters for reliable robust variance estimation. Adaptive estimation produced a 15.4 percent median increase in standard errors compared with unadjusted estimators, yielding conservative inference. These findings demonstrate that routine multilevel meta-analysis requires automated diagnostic safeguards absent from current software. The scope is limited to dichotomous and continuous outcomes and cannot support network meta-analysis or multivariate correlated endpoints.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Do standard multilevel meta-analysis methods fail on real-world Cochrane data rather than idealized simulations, and we developed MLMResearch, an R companion to MLM501. This provides evaluation of restricted maximum likelihood and robust variance estimation across 501 Cochrane datasets with automated detection of convergence failures, variance collapse, and small-sample bias. The package uses adaptive robust variance estimation selecting optimal corrections based on cluster count, it applies CR2 Satterthwaite adjustments when clusters fall below 40. The diagnostics revealed variance collapse in 42 percent of three-level REML models with median degrees of freedom of 8.4 (IQR 5.2 to 12.1). 78 percent had insufficient clusters for reliable robust variance estimation; adaptive estimation produced a 15.4 percent median increase in standard errors compared with unadjusted estimators which yielded conservative inference. These findings demonstrate that routine multilevel meta-analysis requires automated diagnostic safeguards absent from current software. The scope is limited to dichotomous and continuous outcomes at the moment.
<!-- END-REWRITE -->

_Line range 8568-8642 in rewrite-workbook.txt_

---

## Entry 114 ([117/921]) — Multilevelerror

<details><summary>Metadata</summary>

```
TITLE: Multilevelerror: Influence Diagnostics for Three-Level Meta-Analysis
TYPE: methods  |  ESTIMAND: Median Cook distance (IQR)
DATA: Assink 2016 dataset (100 effects, 18 studies) via metadat
PATH: C:\Projects\Multilevelerror
```

</details>

### Original (frozen — do not edit)

```
How reliably do pooled estimates from three-level meta-analytic models remain stable when individual effects or entire studies are removed? We developed the Multilevelerror R package extending metafor rma.mv objects with leave-one-effect-out and leave-one-study-out influence diagnostics including Cook distance, DFBETAS, and variance component stability monitoring at level-two and level-three hierarchies. The algorithm iteratively refits the multilevel model after removing each unit, computing multivariate distance between original and reduced coefficient vectors scaled by the inverse covariance matrix. Applied to the Assink 2016 dataset with 100 effect sizes nested within 18 studies, median Cook distance was 0.08 (IQR 0.03 to 0.22), with 2 studies exceeding the threshold, accounting for 38 percent of total level-three heterogeneity. Parallel processing reduced computation time by 74 percent on an eight-core machine compared with sequential execution. These diagnostics enable researchers to identify fragile pooled estimates in dependent-effects meta-analyses before publication. A limitation is that the implementation supports only intercept-only three-level models without moderator-inclusive specifications.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
How reliably do pooled estimates from three-level meta-analytic models show stability when individual effects are removed? We developed the Multilevelerror R package extending metafor rma.mv objects with leave-one-effect-out diagnostics for dependent-effects meta-analysis. The algorithm iteratively refits the multilevel model after removing each unit, computing multivariate distance between original and reduced coefficient vectors scaled by the inverse covariance matrix. Applied to the Assink 2016 dataset with 100 effect sizes nested within 18 studies, median Cook's distance was 0.004 (95% CI 0.001 to 0.019) with two effects exceeding the conventional cutoff. Parallel processing reduced computation time by 74 percent on an eight-core machine compared with sequential refitting. These diagnostics enable researchers to identify fragile pooled estimates in dependent-effects meta-analyses before publication. The implementation supports only intercept-only three-level models without moderators.
<!-- END-REWRITE -->

_Line range 8643-8717 in rewrite-workbook.txt_

---

## Entry 115 ([118/921]) — Multipledatameta

<details><summary>Metadata</summary>

```
TITLE: Multiple Data Source Meta-Analysis: Pooling Mixed-Format Study Results
TYPE: methods  |  ESTIMAND: Standardized mean difference
DATA: Mixed-format study data (8 conversion types via esc package)
PATH: C:\Projects\Multipledatameta
```

</details>

### Original (frozen — do not edit)

```
How can meta-analysts pool studies when primary reports present results in fundamentally different statistical formats? We created a Shiny web application that accepts mixed-format data including means with standard errors, regression coefficients, standardized betas, correlations, F statistics, t statistics, chi-squared values, and p-values, converting each to standardized mean difference using the esc R package. The application performs random-effects meta-analysis via metafor with automated heterogeneity estimation, producing forest plots, funnel plots, Baujat plots, influence diagnostics, and cumulative meta-analysis alongside downloadable ZIP archives. Across 8 conversion pathways, internal validation confirmed that round-trip effect size conversions preserved original estimates within a tolerance of 0.001 standardized mean difference units. Leave-one-out diagnostics and Baujat plots jointly flagged studies contributing disproportionate heterogeneity across all tested configurations. This tool eliminates the manual conversion step that commonly introduces transcription errors into mixed-format systematic reviews. A limitation is that the application handles only two-group comparisons and does not support hazard ratios or diagnostic accuracy measures.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Can meta-analysts pool studies when primary reports present results in different statistical formats? We created a Shiny web application that accepts mixed-format data including means with standard errors, medians with ranges, t-statistics, F-statistics, and p-values with sample sizes, converting each to standardized mean difference using the esc R package. The application performs random-effects meta-analysis via metafor with automated heterogeneity estimation, forest plots, funnel plots, and influence diagnostics. In 8 conversion pathways, internal validation confirmed that round-trip effect size conversions agreed within 0.001 units of the original input values. Leave-one-out diagnostics and Baujat plots jointly flagged studies contributing disproportionate influence or heterogeneity. This tool removes the manual conversion step that commonly introduces transcription errors into mixed-format syntheses. The application handles only two-group comparisons and does not support hazard ratios or diagnostic accuracy measures.
<!-- END-REWRITE -->

_Line range 8718-8792 in rewrite-workbook.txt_

---

## Entry 116 ([119/921]) — MultiverseMA

<details><summary>Metadata</summary>

```
TITLE: MultiverseMA: Browser-Based Multiverse Meta-Analysis Engine
TYPE: methods  |  ESTIMAND: Specification concordance
DATA: BCG vaccine, aspirin-stroke, omega-3 (built-in datasets)
PATH: C:\Models\MultiverseMA
```

</details>

### Original (frozen — do not edit)

```
Can a browser-based multiverse engine systematically enumerate all defensible analytic specifications and reveal whether meta-analytic conclusions are robust or fragile? Three built-in datasets were analyzed: BCG vaccine (13 studies), aspirin-stroke (6 studies), and omega-3 cardiovascular mortality (8 studies), spanning diverse clinical domains. MultiverseMA, a single-file HTML application of 2,430 lines, generates the full Cartesian product across seven decision dimensions including estimator choice, CI method, outlier handling, and publication bias adjustment. The BCG dataset yielded a median log-RR of -0.633 (95% CI -0.97 to -0.30) with 100% significance concordance across all 48 specifications. The aspirin-stroke dataset revealed fragility, with significance flipping under alternative estimator and inclusion choices, while omega-3 showed high between-specification heterogeneity. This tool is the first browser-based multiverse meta-analysis engine, validated by 33 Selenium tests, enabling transparent robustness assessment without software installation or programming. A limitation is that the engine currently supports univariate pairwise meta-analysis only and does not incorporate network or diagnostic accuracy models.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Can a browser-based multiverse engine enumerate all defensible analytic specifications to reveal whether meta-analytic conclusions are robust or fragile? Three built-in datasets were analyzed: BCG vaccine (13 studies), aspirin-stroke (6 studies), and omega-3 cardiovascular mortality (8 studies), these span diverse clinical domains. MultiverseMA, a single-file HTML application of 2,430 lines, generates the full Cartesian product across seven dimensions including estimator choice, CI method, outlier handling, and publication bias adjustment. The BCG dataset yielded a median log-RR of -0.633 (95% CI -0.97 to -0.30), there was 100% significance concordance across all 48 specifications. The aspirin-stroke dataset revealed fragility, with significance flipping under alternative estimator and inclusion choices. The omega-3 showed high between-specification heterogeneity, this tool is the first browser-based multiverse meta-analysis engine, it is validated by 33 Selenium tests. A limitation is that the engine currently supports only univariate pairwise meta-analysis only.
<!-- END-REWRITE -->

_Line range 8793-8867 in rewrite-workbook.txt_

---

## Entry 117 ([120/921]) — my-python-project

<details><summary>Metadata</summary>

```
TITLE: IPDAnalysis: Unified Python Interface for Individual Patient Data Meta-Analysis
TYPE: methods  |  ESTIMAND: Hazard ratio, odds ratio, mean difference
DATA: Survival, binary, and continuous IPD datasets with 30 dependencies
PATH: C:\Projects\my-python-project
```

</details>

### Original (frozen — do not edit)

```
Can a reproducibility capsule turn an evidence-synthesis repository into a reviewer-auditable submission without restaging the workflow? We audited the shipped project using 13 source files, 3 test files, 1 manuscript or guide files, and 0 dashboard or figure assets committed locally. The capsule packages a micro-paper, a machine-readable config, an interactive reader, and a protocol so the repository can be inspected across reviewers. Across the inventory, the repository yields a documentation proportion of 0.06, with file-count range 0-13 across core surfaces, while exposing 1 entry points and 30 declared dependencies. Git metadata, file counts, and copied assets provide a stable local audit trail even when engine outputs remain outside the submission bundle. This packaging step converts a diffuse codebase into a citable, inspectable micro-publication suitable for rapid editorial triage and downstream peer review. The capsule does not verify scientific correctness itself; it standardizes what reviewers receive first, and deeper validation still depends on tests and manuscripts.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Can a Python package provide a unified interface for individual patient data meta-analysis across survival, binary, and continuous outcomes? We developed IPDAnalysis implementing factory methods for Cox proportional hazards, logistic regression, and linear mixed-effects models with 30 dependencies including lifelines and statsmodels. The package routes each outcome type to the appropriate one-stage model with random-effects specification, stratified baseline hazards, and automated convergence checking. 3 automated tests confirmed correct hazard ratio extraction, odds ratio computation, and mean difference estimation across all 3 supported outcome types with 0 failures. Edge-case handling includes graceful fallback when models fail to converge and exclusion of studies with insufficient events for stratified analysis. A Python-native IPD meta-analysis tool lowers the barrier for researchers whose primary data pipelines already run in Python rather than R. The package currently lacks two-stage methods, Bayesian hierarchical alternatives, and network IPD synthesis limiting it to one-stage frequentist pooling.
<!-- END-REWRITE -->

_Line range 8868-8942 in rewrite-workbook.txt_

---

## Entry 118 ([121/921]) — New_Heterogeneity_Model

<details><summary>Metadata</summary>

```
TITLE: Adaptive Shrinkage Estimator for Heterogeneity in Small-Sample Meta-Analysis
TYPE: methods  |  ESTIMAND: Tau-squared MSE reduction
DATA: Pairwise70 Heterogeneity Atlas (17,236 Cochrane meta-analyses)
PATH: C:\Models\New_Heterogeneity_Model
```

</details>

### Original (frozen — do not edit)

```
Can outcome-specific empirical priors from the Cochrane evidence base stabilize heterogeneity estimation in small meta-analyses? The Adaptive Shrinkage Estimator draws on outcome-stratified priors derived from 17,236 Cochrane meta-analyses in the Pairwise70 Heterogeneity Atlas, spanning nine strata defined by outcome type and objectivity classification. ASE computes a precision-weighted average of the DerSimonian-Laird estimate and the empirical prior mean, with conflict-aware detection mechanism that increases data trust when observed heterogeneity deviates from the prior. Simulation across 24 scenarios showed ASE reduced median tau-squared MSE by 14 to 65 percent at k equals 3 (95% CI coverage 93.8 to 96.0 percent) under Hartung-Knapp-Sidik-Jonkman adjustment. Ablation confirmed that HKSJ drove coverage gains while ASE independently reduced tau-squared bias. The method converges to standard DerSimonian-Laird as k grows, with shrinkage weight exceeding 0.99 at k equals 20 and true tau-squared near zero. However, a limitation is that the variance approximation may be imprecise when within-study variances differ substantially across included studies.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Will outcome-specific empirical priors from the Cochrane evidence base stabilize heterogeneity estimation in small meta-analyses? The Adaptive Shrinkage Estimator uses outcome-stratified priors derived from 17,236 Cochrane meta-analyses in the Pairwise70 Heterogeneity Atlas, it spans nine strata defined by outcome type and objectivity classification. ASE computes a precision-weighted average of the DerSimonian-Laird estimate and the empirical prior mean (with conflict-aware detection mechanism that increases data trust when observed heterogeneity deviates from the prior). Simulation across 24 scenarios showed ASE reduced median tau-squared MSE by 14 to 65 percent at k equals 3 (95% CI coverage 93.8 to 96.0 percent) (under Hartung-Knapp-Sidik-Jonkman adjustment). Ablation confirmed that HKSJ drove coverage gain; aSE independently reduced tau-squared bias. The method converges to standard DerSimonian-Laird as k grows, with shrinkage weight exceeding 0.99 at k equals 20; true tau-squared near zero. Variance approximation may be imprecise when within-study variances differ substantially across included studies.
<!-- END-REWRITE -->

_Line range 8943-9017 in rewrite-workbook.txt_

---

## Entry 119 ([122/921]) — nma-dose-response-app

<details><summary>Metadata</summary>

```
TITLE: NMA Dose-Response Studio: Browser-Based Network Meta-Analysis with Dose-Response Modeling
TYPE: methods  |  ESTIMAND: Pooled treatment effect with dose-response curve
DATA: R metafor and netmeta validation benchmarks
PATH: C:\HTML apps\nma-dose-response-app
```

</details>

### Original (frozen — do not edit)

```
Can network meta-analysis be combined with dose-response modeling in a single browser environment accessible to clinical researchers? NMA Dose-Response Studio v2.0.1 is a browser application implementing network meta-analysis with five heterogeneity estimators, six dose-response model families including Emax and fractional polynomials, Bayesian model averaging, and diagnostic accuracy synthesis, validated with 79 of 79 tests passing against R metafor. The platform provides SUCRA and P-score ranking, node-splitting inconsistency tests, eight publication bias methods, and data quality checks including GRIME and SPRITE with keyboard accessibility. All heterogeneity estimates, pooled effects, and ranking probabilities matched reference R packages within pre-specified tolerances across the validation suite. Bootstrap analyses using reproducible seeds with up to 10,000 iterations confirmed stable treatment rankings and consistent confidence intervals. These results demonstrate that complex multi-method evidence synthesis can operate reliably within browser computation constraints. However, the limitation of client-side Gaussian process fitting means very large treatment networks may exhaust available memory before convergence is achieved.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Can network meta-analysis with dose-response modeling be done in a single browser environment ? NMA Dose-Response Studio v2.0.1 is a browser application implementing network meta-analysis with five heterogeneity estimators, six dose-response model families including Emax and fractional polynomials, Bayesian model averaging, and diagnostic accuracy synthesis. It is validated with 79 of 79 tests passing against R metafor. The platform provides SUCRA and P-score ranking, node-splitting inconsistency tests, eight publication bias methods, and data quality checks including GRIME and SPRITE with keyboard accessibility. All heterogeneity estimates, pooled effects, and ranking probabilities - match reference R packages within pre-specified tolerances across the validation suite. Bootstrap analyses using reproducible seeds with up to 10,000 iterations confirmed the stable treatment rankings and consistent confidence intervals, these results demonstrate that complex multi-method evidence synthesis can operate within browser constraints. However, the limitation of client-side Gaussian process fitting is such that large treatment networks may exhaust available memory before convergence.
<!-- END-REWRITE -->

_Line range 9018-9092 in rewrite-workbook.txt_

---

## Entry 120 ([123/921]) — NMAhtml

<details><summary>Metadata</summary>

```
TITLE: NMA Pro: A Browser-Based Network Meta-Analysis Platform with Integrated Rapid Review
TYPE: methods  |  ESTIMAND: Pooled treatment effect (SMD/OR/RR)
DATA: Six metafor benchmark scenarios; PubMed/OpenAlex/CT.gov APIs
PATH: C:\HTML apps\NMAhtml
```

</details>

### Original (frozen — do not edit)

```
Can a single browser file replace the multi-tool workflow of network meta-analysis, from literature search through certainty assessment? NMA Pro v8.0 is a 14,313-line self-contained HTML application implementing frequentist NMA with four heterogeneity estimators, Bayesian Monte Carlo, component NMA, dose-response modeling, and eight publication bias methods across six benchmark scenarios. The platform integrates PubMed, OpenAlex, and ClinicalTrials.gov queries for abstract screening with deduplication, and implements CINeMA and GRADE certainty frameworks alongside statistical output. All six validation scenarios passed with maximum absolute error of 0.000649 (95% CI 0.000082 to 0.001216) for pooled effects and 0.000197 for tau-squared against R metafor. Ranking reproducibility was ensured through a seeded xoshiro128-star-star pseudorandom generator with 1,500 Monte Carlo simulations producing identical P-scores across sessions. These results suggest browser-native NMA can match dedicated statistical packages while reducing workflow fragmentation for clinical researchers. However, the tool cannot yet replace server-based Bayesian frameworks for models requiring extended Markov chain convergence beyond browser memory constraints.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Will a single browser file replace the multi-tool workflow of network meta-analysis, and this is from literature search through certainty assessment. NMA Pro v8.0 is a self-contained HTML application implementing frequentist NMA with four heterogeneity estimators, Bayesian Monte Carlo, component NMA, dose-response modeling, and eight publication bias methods across six benchmark scenarios. The platform also integrates PubMed, OpenAlex, and ClinicalTrials.gov queries for abstract screening with deduplication, it implements CINeMA and GRADE certainty frameworks alongside statistical output. All six validation scenarios passed with maximum absolute error of 0.000649 (95% CI 0.000082 to 0.001216) for pooled effects (0.000197 for tau-squared against R metafor). Ranking reproducibility was ensured through a seeded xoshiro128-star-star pseudorandom generator with 1,500 Monte Carlo simulations, this produced identical P-scores across sessions. These results suggest browser-native NMA can match dedicated statistical packages while reducing workflow fragmentation for clinical researchers. The tool cannot yet replace server-based Bayesian frameworks for extended Markov chain convergence beyond browser memory constraints.
<!-- END-REWRITE -->

_Line range 9093-9167 in rewrite-workbook.txt_

---

## Entry 121 ([124/921]) — nmapaper111025

<details><summary>Metadata</summary>

```
TITLE: nmatransport: Population-Transported Network Meta-Analysis with Entropy Balancing
TYPE: methods  |  ESTIMAND: P-score (treatment ranking probability)
DATA: 20 simulated trials, 4 treatments, age/BMI effect modifiers
PATH: C:\Projects\nmapaper111025
```

</details>

### Original (frozen — do not edit)

```
Can a reproducibility capsule turn an evidence-synthesis repository into a reviewer-auditable submission without restaging the workflow? We audited the shipped project using 2 source files, 2 test files, 2 manuscript or guide files, and 0 dashboard or figure assets committed locally. The capsule packages a micro-paper, a machine-readable config, an interactive reader, and a protocol so the repository can be inspected across reviewers. Across the inventory, the repository yields a documentation proportion of 0.33, with file-count range 0-2 across core surfaces, while exposing 2 entry points and 11 declared dependencies. Git metadata, file counts, and copied assets provide a stable local audit trail even when engine outputs remain outside the submission bundle. This packaging step converts a diffuse codebase into a citable, inspectable micro-publication suitable for rapid editorial triage and downstream peer review. The capsule does not verify scientific correctness itself; it standardizes what reviewers receive first, and deeper validation still depends on tests and manuscripts.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
How do treatment rankings in network meta-analysis change when transported to a target population with different baseline characteristics? We simulated 20 trials comparing four treatments with age and BMI as effect modifiers generating study-level aggregate data with known treatment-covariate interactions. The nmatransport R package implements transitivity assessment via covariate distance matrices, entropy balancing to reweight studies toward a target distribution, and transported NMA with adjusted standard errors. Standard NMA ranked treatment A optimal with P-score 0.85 while transported NMA for an older higher-BMI population ranked treatment C optimal with P-score 0.91 (95% CI 0.82 to 0.96). Transitivity diagnostics confirmed covariate imbalance and entropy-balanced weights reduced standardized mean differences below 0.05 for both modifiers across all comparisons. Population-specific rankings can differ substantially from standard NMA supporting transportability adjustment when target populations differ from trial samples. Entropy balancing on aggregate data adjusts only reported means not full distributions and validation uses simulated rather than empirical trial data.
<!-- END-REWRITE -->

_Line range 9168-9242 in rewrite-workbook.txt_

---

## Entry 122 ([125/921]) — NNTMapper

<details><summary>Metadata</summary>

```
TITLE: NNTMapper: Converting Meta-Analytic Effects into Population-Specific Number Needed to Treat with Heterogeneity Propagation
TYPE: methods  |  ESTIMAND: Number Needed to Treat across baseline risk range
DATA: 3 cardiovascular validation examples (SGLT2i, statins, aspirin)
PATH: C:\Models\NNTMapper
```

</details>

### Original (frozen — do not edit)

```
How does the Number Needed to Treat from a meta-analysis vary across patient populations with different baseline risks, and how should heterogeneity propagate to this metric? We validated NNTMapper against R using three cardiovascular examples: SGLT2 inhibitors in heart failure, statins for primary prevention, and aspirin for secondary prevention. The tool converts pooled effects into population-specific NNT, absolute risk reduction, and relative risk reduction across user-specified baseline risks, with prediction intervals incorporating between-study variance via the t-distribution. For SGLT2 inhibitors with pooled OR 0.74 (95% CI 0.66 to 0.83) at 20 percent baseline risk, NNTMapper computed NNT of 23 (CI 17 to 37), matching R to machine precision. Decision curve analysis identified net benefit thresholds where treatment decisions shifted across the baseline risk spectrum. Converting relative effects to absolute patient-relevant metrics makes meta-analytic evidence directly actionable for clinical decision-making. The tool is limited to single pooled estimates and cannot incorporate patient-level risk stratification or competing risks.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Does the Number Needed to Treat from a meta-analysis vary across patient populations with different baseline risks. How should heterogeneity propagate to this metric, and we validated NNTMapper against R using three cardiovascular examples. These were SGLT2 inhibitors in heart failure, statins for primary prevention, and aspirin for secondary prevention. The tool then converted pooled effects into population-specific NNT, absolute risk reduction, and relative risk reduction across user-specified baseline risks, it also gave prediction intervals incorporating between-study variance via the t-distribution. For SGLT2 inhibitors with pooled OR 0.74 (95% CI 0.66 to 0.83) at 20 percent baseline risk: NNTMapper computed NNT of 23 (CI 17 to 37). This matched R to machine precision; decision curve analysis showed net benefit thresholds where treatment decisions shifted across the baseline risk spectrum. Converting the relative effects to absolute patient-relevant metrics makes meta-analytic evidence directly actionable for decision-making, the tool is limited to single pooled estimates.
<!-- END-REWRITE -->

_Line range 9243-9317 in rewrite-workbook.txt_

---

## Entry 123 ([126/921]) — OutcomeReportingBias

<details><summary>Metadata</summary>

```
TITLE: Outcome Reporting Bias Risk in 473 Cochrane Meta-Analyses: An Excess Significance Approach
TYPE: meta-research  |  ESTIMAND: ORB risk prevalence
DATA: 473 Cochrane reviews from Pairwise70 dataset (k >= 3)
PATH: C:\OutcomeReportingBias
```

</details>

### Original (frozen — do not edit)

```
What is the prevalence of statistical patterns consistent with outcome reporting bias across Cochrane systematic reviews? We applied excess significance testing and three complementary indicators to 473 Cochrane reviews from the Pairwise70 dataset, each containing at least three primary studies. A composite scoring system combining excess significance, heterogeneity, outlier ratio, and precision asymmetry classified reviews into Low, Moderate, and High risk categories. The prevalence of High risk was 15.2 percent (72 of 473), while 20.7 percent were Moderate risk and 64.1 percent were Low risk. Mean excess significance was 0.47 studies, with 23.5 percent of reviews exceeding one extra significant study and 11.6 percent exceeding two. These findings suggest that roughly one in six Cochrane reviews exhibits statistical signatures warranting closer scrutiny of pre-registration fidelity and outcome switching. A limitation is that statistical proxy indicators cannot distinguish outcome reporting bias from publication bias or other selective reporting mechanisms.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Is the prevalence of statistical patterns consistent with outcome reporting bias across Cochrane systematic reviews? We applied excess significance testing and three complementary indicators using 403 Cochrane reviews from the Pairwise70 dataset, each contained at least three primary studies. A composite scoring system combining excess significance, heterogeneity, outlier ratio, and precision asymmetry then classified reviews into Low, Moderate, and High risk categories. The prevalence of High risk was 16.1% (65 of 403, 95% CI 12.6-20.1%), the mean excess significance of 2.83 and mean I-squared of 70.3% compared to 14.8% in Low risk reviews. Spearman correlation between excess significance and heterogeneity was 0.36, this confirms that reviews with more significant results than expected showed greater between-study variability. These findings suggest that one in six Cochrane reviews shows statistical signatures warranting scrutiny of pre-registration fidelity and outcome switching. A limitation is that statistical proxy indicators cannot distinguish outcome reporting bias from other selective reporting mechanisms.
<!-- END-REWRITE -->

_Line range 9318-9392 in rewrite-workbook.txt_

---

## Entry 124 ([127/921]) — OverlapDetector

<details><summary>Metadata</summary>

```
TITLE: Study Overlap Across 591 Cochrane Reviews: Quantifying Non-Independence for Meta-Research
TYPE: meta-research  |  ESTIMAND: Corrected Covered Area (CCA)
DATA: 591 Cochrane reviews from Pairwise70 dataset (11,899 unique studies)
PATH: C:\OverlapDetector
```

</details>

### Original (frozen — do not edit)

```
How much primary study overlap exists across large collections of Cochrane systematic reviews, and does this non-independence threaten the validity of methodological meta-research? We mapped all primary studies across 591 Cochrane reviews from the Pairwise70 dataset using normalized first-author-year keys to identify shared studies across reviews. The pipeline computed the Corrected Covered Area index, pairwise Jaccard similarity coefficients, and study frequency distributions across all 174,345 review pairs. The prevalence of overlap was minimal: CCA was 0.0001, with only 590 of 11,899 unique studies (5.0 percent) appearing in more than one review. There were 875 overlapping review pairs, and the most overlapping pair shared 43 studies with a Jaccard coefficient of 0.37. These results validate the Pairwise70 dataset as a source of largely independent meta-analyses suitable for large-scale methodological benchmarking. A limitation is that first-author-year matching may produce false positives when different studies share identical author surnames and publication years.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Is there primary study overlap across large collections of Cochrane systematic reviews. Does this non-independence threaten the validity of methodological meta-research, and we mapped all primary studies across 501 Cochrane reviews from the Pairwise70 dataset using normalized first-author-year keys to identify shared studies. The pipeline then computed the Corrected Covered Area index, pairwise Jaccard similarity coefficients, and study frequency distributions across all 125,250 review pairs. The prevalence of overlap was minimal. CCA was 0.0001 (95% CI 0.00005-0.00018), with only 444 of 10,006 unique studies (4.4%) appearing in more than one review. In the 604 overlapping pairs, the most overlapping pair shared 43 studies with a Jaccard coefficient of 0.37. 72% of pairs shared only one study, these results validate the Pairwise70 dataset as a source of largely independent meta-analyses. A limitation is that first-author-year matching may produce false positives if different studies share identical author surnames and publication years.
<!-- END-REWRITE -->

_Line range 9393-9467 in rewrite-workbook.txt_

---

## Entry 125 ([128/921]) — OverlapMatrix

<details><summary>Metadata</summary>

```
TITLE: Overlap Matrix and Corrected Covered Area Calculator for Umbrella Reviews
TYPE: methods  |  ESTIMAND: Corrected Covered Area (CCA)
DATA: User-supplied study lists per meta-analysis
PATH: C:\Models\OverlapMatrix
```

</details>

### Original (frozen — do not edit)

```
How can reviewers conducting umbrella reviews systematically quantify primary-study overlap across included meta-analyses without manual cross-tabulation? We implemented the Pieper corrected covered area method in a single-file browser application that accepts study lists for any number of included meta-analyses. The tool constructs a binary citation matrix, computes the corrected covered area index, generates pairwise Jaccard coefficients, and renders an interactive color-coded heatmap with hierarchical clustering and a downloadable dendrogram. In a demonstration dataset of 8 meta-analyses sharing 47 primary studies, the corrected covered area proportion was 0.34 (95% CI 0.21 to 0.47 via bootstrap), indicating moderate overlap. Leave-one-out removal of the most-cited meta-analysis reduced the index to 0.21, confirming that one dominant review drove most observed redundancy. The calculator enables transparent reporting of overlap in umbrella reviews, directly supporting the PRIOR guidelines for handling overlapping evidence in practice. One limitation is that the tool does not yet model direction-of-effect differences among studies contributing to different meta-analyses.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Can reviewers conducting umbrella reviews systematically quantify primary-study overlap across included meta-analyses (without manual cross-tabulation)? We implemented the Pieper corrected covered area method (in a single-file browser application) that accepts study lists for any number of included meta-analyses. The tool then constructs a binary citation matrix and computes the corrected covered area index. It generates pairwise Jaccard coefficients, and renders an interactive color-coded heatmap with hierarchical clustering and a downloadable dendrogram. In a demonstration dataset of 8 meta-analyses sharing 47 primary studies the corrected covered area proportion was 0.34 (95% CI 0.21 to 0.47 via bootstrap) This indicates moderate overlap. Leave-one-out removal of the most-cited meta-analysis reduced the index to 0.21, this confirms one dominant review drove most observed redundancy, the calculator enables transparent reporting of overlap in umbrella reviews. This directly supports the PRIOR guidelines for handling overlapping evidence in practice; one limitation is that the tool does not yet model direction-of-effect differences among studies.
<!-- END-REWRITE -->

_Line range 9468-9542 in rewrite-workbook.txt_

---

## Entry 126 ([129/921]) — Pairwise70

<details><summary>Metadata</summary>

```
TITLE: Pairwise70: Standardized Dataset of 501 Cochrane Meta-Analyses
TYPE: data  |  ESTIMAND: Fragility index
DATA: 501 Cochrane systematic reviews, 4,424 meta-analyses, ~50,000 studies
PATH: C:\Models\Pairwise70
```

</details>

### Original (frozen — do not edit)

```
Can a standardized open dataset of Cochrane meta-analyses enable scalable meta-research without manual data re-extraction from individual systematic reviews? We extracted and cleaned 501 pairwise meta-analysis datasets from Cochrane systematic reviews, producing the Pairwise70 R data package containing over 4,400 meta-analyses from 473 reviews with standardized columns across binary, continuous, and inverse-variance outcome types. Each dataset preserves study identifiers, outcome descriptions, intervention labels, subgroup classifications, and review DOIs in a machine-readable format compatible with metafor and meta R packages. The fragility index validation across 4,424 meta-analyses yielded a median fragility score of 0.31 (95% CI 0.29-0.33) with classifications from robust to high fragility. Cross-validation against original RevMan data files confirmed extraction fidelity with zero discrepancies in effect direction or significance across all 501 reviews. Pairwise70 provides a research-ready open resource for methodological studies requiring large-scale standardized meta-analytic benchmarks. The limitation of Cochrane-only sourcing means non-Cochrane reviews and grey literature meta-analyses remain unrepresented in this data collection.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Can a standardized open dataset of Cochrane meta-analyses allow meta-research without manual data re-extraction from individual systematic reviews? We extracted and cleaned 501 pairwise meta-analysis datasets from Cochrane systematic reviews. This produced the Pairwise70 R data package containing over 4,400 meta-analyses from 473 reviews with standardized columns across binary, continuous, and inverse-variance outcome types. Each dataset preserves study identifiers, outcome descriptions, intervention labels, subgroup classifications, and review DOIs in a machine-readable format compatible with metafor and meta R packages. The fragility index validation across 4,424 meta-analyses then yielded a median fragility score of 0.31 (95% CI 0.29-0.33) (with classifications from robust to high fragility. Cross-validation against original RevMan data files confirmed extraction fidelity with zero discrepancies in effect direction or significance across all 501 reviews). Pairwise70 provides a research-ready open resource for methodological studies, the limitation of Cochrane-only sourcing means non-Cochrane reviews and grey literature meta-analyses remain unrepresented.
<!-- END-REWRITE -->

_Line range 9543-9617 in rewrite-workbook.txt_

---

## Entry 127 ([131/921]) — Pairwiseai

<details><summary>Metadata</summary>

```
TITLE: TruthCert PairwisePro: Browser-Based Pairwise Meta-Analysis with Regional Health-Economic Overlays
TYPE: methods  |  ESTIMAND: Pooled effect size (OR/RR/MD/SMD)
DATA: 13 African countries, 7 disease groups, metafor validation benchmarks
PATH: C:\HTML apps\Pairwiseai
```

</details>

### Original (frozen — do not edit)

```
Can a unified browser application deliver production-grade pairwise meta-analysis across thirteen regional health-economic contexts simultaneously? TruthCert PairwisePro v1.0 is a 27,076-line single-file HTML application providing random-effects meta-analysis with DerSimonian-Laird, REML, and Paule-Mandel estimators, HKSJ adjustment, prediction intervals, and thirteen country-specific cost-effectiveness overlays for Africa-focused health technology assessment applications. The system implements forest plots, funnel plots, Egger regression, trim-and-fill, leave-one-out sensitivity, and cumulative meta-analysis with automated GRADE certainty assessment, all running client-side without server dependencies or installation. Pooled estimates matched R metafor within 0.0001 for tau-squared across all validation benchmarks, with 101 of 101 regression tests passing on the production bundle. Sensitivity analysis confirmed stable conclusions across all three heterogeneity estimators and both confidence interval methods for each benchmark dataset. This architecture demonstrates that a zero-installation browser tool can serve both statistical rigor and health-economic translation in resource-limited settings. Nonetheless, the limitation of fixed country-level cost parameters means site-specific pharmacoeconomic adaptation requires manual override by local analysts.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Will a unified browser application deliver production-grade pairwise meta-analysis across thirteen regional health-economic contexts simultaneously? TruthCert PairwisePro v1.0 is a single-file HTML application providing random-effects meta-analysis with DerSimonian-Laird, REML, and Paule-Mandel estimators, HKSJ adjustment and prediction intervals. It has thirteen country-specific cost-effectiveness overlays for Africa-focused health technology assessment applications, the system also implements forest plots, funnel plots, Egger regression, trim-and-fill, leave-one-out sensitivity, and cumulative meta-analysis with automated GRADE certainty assessment. Pooled estimates matched R metafor within 0.0001 for tau-squared across all validation benchmarks; 101 of 101 regression tests passing on the production bundle. Sensitivity analysis confirmed stable conclusions across all three heterogeneity estimators, both confidence interval methods for each benchmark dataset. This architecture demonstrates that a browser tool can serve both statistical rigor and health-economic translation. Fixed country-level cost parameters means site-specific pharmacoeconomic adaptation requires manual override by local analysts.
<!-- END-REWRITE -->

_Line range 9618-9692 in rewrite-workbook.txt_

---

## Entry 128 ([132/921]) — Paper1

<details><summary>Metadata</summary>

```
TITLE: Bootstrap-Aggregated Penalized Meta-Regression for Small-Sample Evidence Synthesis
TYPE: methods  |  ESTIMAND: R-squared heterogeneity
DATA: BCG, Berkey, Hackshaw, Konstantopoulos, Teacher datasets from metadat
PATH: C:\Projects\Paper1
```

</details>

### Original (frozen — do not edit)

```
Can bootstrap aggregation resolve the regularization paradox whereby LASSO increases overfitting in small-sample meta-regression settings? We developed BAP-MR using five benchmark datasets from the metadat R package including BCG vaccination, Berkey periodontal, and Konstantopoulos multi-site trials with study counts from ten to forty-one. The method applies LASSO across bootstrap resamples of the meta-analytic dataset and averages the resulting penalized coefficients and heterogeneity estimates to stabilize lambda selection. In null simulations with ten studies and two moderators, standard LASSO produced 30.6 percent mean optimism while BAP-MR suppressed optimism to 8.2 percent, outperforming unpenalized restricted maximum likelihood at 13.0 percent. Across all five empirical datasets, BAP-MR consistently delivered the most conservative R-squared-het estimates and resisted spurious moderator discovery plaguing single-pass penalization. Bagging the penalization process provides a principled solution to unstable cross-validation in small-sample evidence synthesis. The limitation of bootstrap resampling is that performance may degrade with extremely small study counts below eight where resamples become insufficiently diverse.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Can bootstrap aggregation resolve the regularization paradox - whereby LASSO increases overfitting in small-sample meta-regression settings? We developed BAP-MR using five benchmark datasets (from the metadat R package including BCG vaccination, Berkey periodontal, and Konstantopoulos multi-site trials with study counts from ten to forty-one). The method applies LASSO across bootstrap resamples of the meta-analytic dataset, it averages the resulting penalized coefficients and heterogeneity estimates to stabilize lambda selection. In null simulations with ten studies and two moderators, standard LASSO produced 30.6 percent mean optimism; bAP-MR suppressed optimism to 8.2 percent, outperforming unpenalized restricted maximum likelihood at 13.0 percent. In all five empirical datasets, BAP-MR consistently delivered the most conservative R-squared-het estimates, it resisted spurious moderator discovery plaguing single-pass penalization. Bagging the penalization process provides a principled solution to unstable cross-validation (in small-sample evidence synthesis). The limitation of bootstrap resampling is that performance may degrade with extremely small study counts below eight.
<!-- END-REWRITE -->

_Line range 9693-9767 in rewrite-workbook.txt_

---

## Entry 129 ([133/921]) — Paper2.111025

<details><summary>Metadata</summary>

```
TITLE: Precision-Weighted Cross-Validation for Unbiased Meta-Regression R-Squared Estimation
TYPE: methods  |  ESTIMAND: Precision-weighted cross-validated R-squared
DATA: 8 canonical datasets (10-56 studies), 1,000 simulated meta-analyses per condition
PATH: C:\Projects\Paper2.111025
```

</details>

### Original (frozen — do not edit)

```
Can a reproducibility capsule turn an evidence-synthesis repository into a reviewer-auditable submission without restaging the workflow? We audited the shipped project using 1 source files, 2 test files, 3 manuscript or guide files, and 8 dashboard or figure assets committed locally. The capsule packages a micro-paper, a machine-readable config, an interactive reader, and a protocol so the repository can be inspected across reviewers. Across the inventory, the repository yields a documentation proportion of 0.21, with file-count range 1-8 across core surfaces, while exposing 2 entry points and 4 declared dependencies. Git metadata, file counts, and copied assets provide a stable local audit trail even when engine outputs remain outside the submission bundle. This packaging step converts a diffuse codebase into a citable, inspectable micro-publication suitable for rapid editorial triage and downstream peer review. The capsule does not verify scientific correctness itself; it standardizes what reviewers receive first, and deeper validation still depends on tests and manuscripts.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Does precision-weighted leave-one-out cross-validation provide unbiased R-squared estimates in meta-regression compared with apparent R-squared? We evaluated eight canonical datasets with study counts from 10 to 56 and predictor counts from one to eight alongside 1,000 simulated meta-analyses per condition varying heterogeneity and true R-squared. Precision-weighted LOOCV uses inverse-variance plus estimated between-study variance as study weights compared against apparent and unweighted cross-validated R-squared under REML. Apparent R-squared severely overestimated explained variance with BCG yielding 64.6 percent versus 6.3 percent precision-weighted (95% CI 0.1 to 18.7) and Passive Smoking giving 81.8 percent unweighted versus 0.6 percent weighted. Under the null with 20 studies apparent R-squared averaged 19.7 percent while precision-weighted cross-validated averaged 10.4 percent confirming substantial optimistic bias. Precision weighting corrects the most misleading R-squared estimates in small meta-regressions where overfitting risk is highest. Evaluation was restricted to leave-one-out with the Borenstein R-squared metric and generalization to alternative cross-validation schemes remains untested.
<!-- END-REWRITE -->

_Line range 9768-9842 in rewrite-workbook.txt_

---

## Entry 130 ([134/921]) — PoolingSuite

<details><summary>Metadata</summary>

```
TITLE: Pooling Suite: Browser-Based Meta-Analysis Engine with Ten Heterogeneity Estimators
TYPE: methods  |  ESTIMAND: Pooled effect (tau-squared comparison)
DATA: BCG vaccine (13 studies), magnesium for MI (8 studies)
PATH: C:\Models\PoolingSuite
```

</details>

### Original (frozen — do not edit)

```
How do methodological choices among heterogeneity estimators and confidence interval methods affect pooled meta-analytic estimates in practice? Two built-in datasets, BCG vaccine (13 studies) and magnesium for myocardial infarction (8 studies), were analyzed across all estimator and CI method combinations. Pooling Suite, a browser-based application of 1,840 lines, implements ten tau-squared estimators and three CI methods, producing a 30-cell comparison table with forest plots, Baujat plots, GOSH analysis, and full influence diagnostics including Cook distance. The BCG dataset showed pooled log-RR ranging from -0.71 (95% CI -1.06 to -0.37) under ML to -0.74 under Hedges, with tau-squared varying from 0.30 to 0.51. Leave-one-out analysis identified the Madras and Chingleput studies as dominant heterogeneity sources across all ten estimators. This tool provides the first side-by-side browser-based comparison of ten meta-analytic estimators, validated against R metafor with 25 Selenium tests. A limitation is that the current version does not implement profile likelihood or Kenward-Roger corrections for small meta-analyses.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
When do methodological choices among heterogeneity estimators and confidence interval methods affect pooled meta-analytic estimates in practice? Using two built-in datasets, BCG vaccine (13 studies) and magnesium for myocardial infarction (8 studies) we analyzed across all estimator and CI method combinations. Pooling Suite app implements ten tau-squared estimators and three CI methods, producing a 30-cell comparison table with forest plots, Baujat plots, GOSH analysis, and full influence diagnostics including Cook distance. The BCG dataset has pooled log-RR ranging from -0.71 (95% CI -1.06 to -0.37) under ML to -0.74 under Hedges (with tau-squared varying from 0.30 to 0.51). The Leave-one-out analysis identified the Madras and Chingleput studies as dominant heterogeneity sources across all ten estimators. This tool also provides the first side-by-side browser-based comparison of ten meta-analytic estimators (validated against R metafor with 25 Selenium tests). The current version does not implement profile likelihood or Kenward-Roger corrections for small meta-analyses.
<!-- END-REWRITE -->

_Line range 9843-9917 in rewrite-workbook.txt_

---

## Entry 131 ([135/921]) — portfolio-site

<details><summary>Metadata</summary>

```
TITLE: Meta-Analysis Methods Lab: A Single-Page Portfolio for 101 Evidence Synthesis Projects
TYPE: showcase  |  ESTIMAND: Project catalog completeness
DATA: 101 project entries, 35 browser tools
PATH: C:\Projects\portfolio-site
```

</details>

### Original (frozen — do not edit)

```
Can a single-page portfolio effectively communicate the scope and validation status of a meta-analysis methods program spanning over one hundred projects? We designed a 794-line static HTML page organized into nine sections covering flagship tools, browser applications, cutting-edge methods, meta-theory, discovery platforms, R packages, health technology assessment suites, and data pipelines. The site renders each project card with lines of code, test counts, target journal, and deployment status through a responsive grid layout with dark-light theming. The catalog includes 101 projects with a median of 25 tests each (95% CI 15 to 42) and 35 browser tools across 17 manuscript targets from BMJ to PLOS ONE. Accessibility audit confirmed WCAG AA contrast compliance for all text and background combinations across both visual theme modes. The architecture requires zero build tools, loading entirely from a single file with no external dependencies. A limitation is that static deployment cannot automatically synchronize project status when underlying repositories are updated.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Will a single-page portfolio effectively communicate the scope and validation status of a meta-analysis methods program spanning over one hundred projects? We have designed a 794-line static HTML page organized into nine sections covering flagship tools, browser applications, cutting-edge methods, meta-theory, discovery platforms, R packages, health technology assessment suites, and data pipelines. The site itself renders each project card with lines of code, test counts, target journal, and deployment status through a responsive grid layout. The catalog includes at least 101 projects with a median of 25 tests each (95% CI 15 to 42) as well as  35 browser tools across 17 manuscript targets from BMJ to PLOS ONE. Accessibility audit confirmed WCAG AA contrast compliance for all text and background combinations. The architecture requires zero build tools, loading entirely from a single file with no external dependencies. Our limitation is that static deployment cannot automatically synchronize project status when underlying repositories are updated.
<!-- END-REWRITE -->

_Line range 9918-9992 in rewrite-workbook.txt_

---

## Entry 132 ([136/921]) — PredictionGap

<details><summary>Metadata</summary>

```
TITLE: The Prediction Gap: 72% of Significant Meta-Analyses Have Null-Spanning Prediction Intervals
TYPE: methods  |  ESTIMAND: False reassurance rate
DATA: Pairwise70 dataset (473 Cochrane reviews)
PATH: C:\PredictionGap
```

</details>

### Original (frozen — do not edit)

```
Can the pooled effect from a statistically significant meta-analysis be expected to apply in the next clinical setting? We computed DerSimonian-Laird random-effects pooled estimates with both confidence and prediction intervals for 473 eligible Cochrane systematic reviews from the Pairwise70 dataset. For each review, the prediction interval was compared against the confidence interval to classify concordance using the t-distribution with k minus two degrees of freedom as the critical value. Of the 217 reviews with a 95% confidence interval excluding the null, 156 had a prediction interval including the null, yielding a false reassurance rate of 71.9 percent. The mean prediction-interval-to-confidence-interval width ratio was 3.14, and 30.7 percent of reviews had I-squared above 50 percent. Nearly three quarters of statistically significant meta-analyses therefore provide misleading confidence that the average treatment effect will replicate in a new clinical setting. However, this analysis is limited to ratio and difference outcomes and cannot address heterogeneity arising from unreported clinical or methodological moderators.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Will the pooled effect from a significant meta-analysis be expected to apply in the next new setting? We computed DerSimonian-Laird random-effects pooled estimates with both confidence and prediction intervals for 403 Cochrane reviews from the Pairwise70 dataset using REML tau-squared estimation. For each review, the prediction interval was compared against the CI to classify concordance using a three-tier system. Of the 189 reviews with a 95% CI excluding the null, 132 had a prediction interval including the null, yielding a false reassurance rate of 69.8 percent. The discordance rose sharply from 42 percent at low heterogeneity to 95 percent at moderate heterogeneity, with mean prediction-to-confidence width ratio of 3.12. Seven in ten significant meta-analyses provide misleading confidence that the effect will hold in new settings. This analysis cannot address heterogeneity arising from unreported clinical or methodological moderators.
<!-- END-REWRITE -->

_Line range 9993-10067 in rewrite-workbook.txt_

---

## Entry 133 ([137/921]) — PRISMAChecker

<details><summary>Metadata</summary>

```
TITLE: PRISMA 2020 Compliance Checker: An Interactive Browser Tool for Systematic Review Reporting Assessment
TYPE: methods  |  ESTIMAND: PRISMA 2020 compliance percentage
DATA: PRISMA 2020 27-item checklist (Page et al. BMJ 2021;372:n71)
PATH: C:\Models\PRISMAChecker
```

</details>

### Original (frozen — do not edit)

```
Does an interactive browser-based tool improve structured compliance evaluation against the 27-item PRISMA 2020 checklist for systematic review reporting? The tool encodes all 27 items across seven sections from Title through Other Information, with four-level grading per item: Reported, Partial, Not Reported, and Not Applicable. Six PRISMA extensions are supported: Searching, Scoping Reviews, Network Meta-Analyses, Diagnostic Test Accuracy, Individual Patient Data, and Protocols. The median compliance score was 74% (IQR 59 to 89%), with a real-time dashboard showing section-level progress bars and an overall score reaching 100% when all applicable items are reported. All 25 Selenium tests passed, confirming correct scoring logic, extension toggling, state persistence via localStorage, and export to CSV, JSON, and clipboard-ready compliance statements. The tool reduces assessment friction by translating a static checklist into a guided interactive workflow with immediate visual feedback. Assessment is limited to the PRISMA 2020 statement and cannot evaluate methodological quality, risk of bias, or certainty of evidence.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Will an interactive browser-based tool improve structured compliance evaluation against the 27-item PRISMA 2020 checklist ? The tool encodes all 27 items across seven sections from Title through Other Information.It has a four-level grading per item: Reported, Partial, Not Reported, and Not Applicable. Six PRISMA extensions are supported: Searching, Scoping Reviews, Network Meta-Analyses, Diagnostic Test Accuracy, Individual Patient Data, and Protocols. A real-time dashboard shows section-level progress bars and an overall score reaching 100% when all applicable items are reported. All 25 Selenium tests passed, confirming correct scoring logic, extension toggling, state persistence via localStorage, and export to CSV, JSON, and clipboard-ready compliance statements. This tool reduces assessment by translating a static checklist into a guided interactive workflow. Assessment is limited to the PRISMA 2020 statement.
<!-- END-REWRITE -->

_Line range 10068-10142 in rewrite-workbook.txt_

---

## Entry 134 ([138/921]) — PRISMAFlow

<details><summary>Metadata</summary>

```
TITLE: PRISMA 2020 Flow Diagram Generator for Systematic Reviews
TYPE: methods  |  ESTIMAND: PRISMA flow diagram compliance
DATA: User-entered record counts across review phases
PATH: C:\Models\PRISMAFlow
```

</details>

### Original (frozen — do not edit)

```
How can systematic reviewers produce publication-ready PRISMA 2020 flow diagrams without specialized graphic design software or tedious manual drawing? We built a browser application that generates compliant four-phase flow diagrams from user-entered record counts across identification, screening, eligibility, and inclusion stages. The generator renders scalable vector graphics with automatic box sizing, arrow routing, color-coded phase labels, and editable exclusion-reason annotations that update in real time as values change. All 20 of 20 automated validation checks passed (100 percent, 95% CI 83 to 100), with downstream arithmetic propagating correctly within 0.1 seconds across all test configurations. Modifying any count automatically propagates downstream calculations, eliminating the arithmetic discrepancies found in approximately 12 percent of manually assembled diagrams. The application provides a zero-installation pathway to transparent reporting for any systematic review team with a standard web browser. One limitation is that the generator supports only the standard four-phase layout without extension-specific adaptations for network or diagnostic test accuracy reviews.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Can systematic reviewers produce publication-ready PRISMA 2020 flow diagrams without specialized graphic design software? We built a browser application that generates compliant four-phase flow diagrams, this is from user-entered record counts across identification, screening, eligibility, and inclusion stages. The generator renders scalable vector graphics with automatic box sizing, arrow routing, color-coded phase labels, and editable exclusion-reason annotations (that update in real time as values change). All 20 of 20 automated validation checks passed (100 percent, 95% CI 83 to 100). Downstream arithmetic propagating correctly within 0.1 seconds across all test configurations; modifying any count then automatically propagates downstream calculations. This eliminates the arithmetic discrepancies found in approximately 12 percent of manually assembled diagrams, the application provides a zero-installation pathway with a standard web browser. One limitation is that the generator supports only the standard four-phase layout.
<!-- END-REWRITE -->

_Line range 10143-10217 in rewrite-workbook.txt_

---

## Entry 135 ([139/921]) — private-website

<details><summary>Metadata</summary>

```
TITLE: OpenPalp: Structured Palpitations Assessment Programme via Clinical Website
TYPE: clinical  |  ESTIMAND: Pathway completion rate
DATA: Clinical pathway data from Friday evening sessions, Wimbledon SW19
PATH: C:\Projects\private-website
```

</details>

### Original (frozen — do not edit)

```
Can a structured palpitations programme delivered via a clinical website reduce unnecessary emergency presentations for low-risk cardiac symptoms? We developed OpenPalp as a GDPR-compliant website for the London Cardiology Clinic offering 30-day KardiaMobile 6L monitoring combined with a six-week lifestyle programme for low-risk palpitations. The site implements schema.org structured data, self-hosted fonts eliminating third-party tracking, responsive editorial design, and progressive disclosure of clinical pathway information across dedicated palpitations and monitoring pages. Across four clinic sessions the median time to first diagnostic ECG recording was 2.5 days (95% CI 1 to 4) with pathway completion rates supporting feasibility of the structured care model. Booking funnel analytics show that pathway page visitors proceed to consultation requests at rates comparable to established telemedicine cardiology platforms. The information architecture separates clinical content from booking mechanics, enabling independent updates to medical guidance without disrupting scheduling. Long-term symptom reduction has not yet been formally evaluated in a controlled study, limiting causal conclusions.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Will a structured palpitations programme delivered via a clinical website reduce unnecessary emergency presentations for low-risk cardiac symptoms? We created OpenPalp as a GDPR-compliant website for the London Cardiology Clinic offering 30-day KardiaMobile 6L monitoring combined with a six-week lifestyle programme for low-risk palpitations. The site implements uses schema.org structured data and self-hosted fonts eliminating third-party tracking. Lighthouse testing confirmed a 98 percent accessibility score with responsive editorial design and progressive disclosure across 5 clinical pathway pages. The information architecture separates clinical content from booking mechanics. This enables independent updates to medical guidance without disrupting scheduling. The Long-term symptom reduction has not yet been formally evaluated in a controlled study, limiting causal conclusions.
<!-- END-REWRITE -->

_Line range 10218-10292 in rewrite-workbook.txt_

---

## Entry 136 ([140/921]) — prognostic-meta

<details><summary>Metadata</summary>

```
TITLE: PrognosisMeta: Browser-Based Prognostic Meta-Analysis Engine
TYPE: methods  |  ESTIMAND: HR
DATA: Three benchmark datasets, R metafor v4.8.0 reference values
PATH: C:\Projects\prognostic-meta
```

</details>

### Original (frozen — do not edit)

```
Can a browser-based application implement publication-quality prognostic meta-analysis methods validated against R metafor? We developed PrognosisMeta, a 29,770-line JavaScript application implementing eight tau-squared estimators, eight publication bias methods, six selection models, Bayesian MCMC with Turner priors, dose-response analysis with eight functional forms, and diagnostic test accuracy including bivariate SROC. The engine pools hazard ratios, odds ratios, risk ratios, and C-statistics using inverse-variance random-effects models with Hartung-Knapp-Sidik-Jonkman adjustment and prediction intervals on appropriate transformed scales. Validation against R metafor across three datasets showed 93.3 percent exact match for pooled HR estimates, 95% CI bounds, tau-squared, and heterogeneity statistics including I-squared and Cochran Q. Sensitivity analyses using all eight estimators confirmed numerical stability with maximum divergence below 0.001 across every test configuration. The application provides an accessible zero-installation platform for prognostic evidence synthesis with full R code export for reproducibility. However, the limitation of client-side computation means very large analyses exceeding 500 studies may encounter browser memory constraints.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Will a browser-based application implement publication-quality prognostic meta-analysis methods (validated against R metafor)? We developed PrognosisMeta, a JavaScript application implementing eight tau-squared estimators, eight publication bias methods, six selection models, Bayesian MCMC with Turner priors, dose-response analysis with eight functional forms, and diagnostic test accuracy including bivariate SROC. The engine pools hazard ratios, odds ratios, risk ratios, and C-statistics using inverse-variance random-effects models with Hartung-Knapp-Sidik-Jonkman adjustment and prediction intervals on appropriate transformed scales. The validation against R metafor across three datasets showed 93.3 percent exact match for pooled HR estimates, 95% CI bounds, tau-squared, and heterogeneity statistics including I-squared and Cochran Q. Our Sensitivity analyses using all eight estimators confirmed numerical stability with maximum divergence below 0.001 (across every test configuration). The application provides a zero-installation platform for prognostic evidence synthesis (with full R code export for reproducibility). The limitation of client-side computation means very large analyses exceeding 500 studies may encounter browser constraints.
<!-- END-REWRITE -->

_Line range 10293-10368 in rewrite-workbook.txt_

---

## Entry 137 ([141/921]) — pub-bias-simulation

<details><summary>Metadata</summary>

```
TITLE: Publication Bias Adjustment Methods: A 135-Scenario Simulation Comparison
TYPE: methods  |  ESTIMAND: RMSE of bias-corrected pooled estimate
DATA: 13,480 simulated meta-analyses across 135 factorial scenarios (3 effect sizes x 3 tau x 3 k x 5 bias
PATH: C:\Projects\pub-bias-simulation
```

</details>

### Original (frozen — do not edit)

```
How do Trim and Fill, PET-PEESE, and the Copas selection model perform for correcting publication bias under varying heterogeneity and study counts in meta-analysis? We simulated 13,480 meta-analyses across 135 scenarios crossing three effect sizes, three heterogeneity levels, three study counts, and five selection mechanisms. Each dataset was analysed with unadjusted random-effects, Trim and Fill, PET-PEESE regression, and Copas maximum-likelihood selection modelling, evaluated by bias, RMSE, and coverage. The Copas model achieved the lowest median RMSE across scenarios with twenty or more studies and maintained 95% CI coverage of 89-96%, while PET-PEESE overcorrected under high heterogeneity with coverage below 50%. All methods were unstable with only ten studies, and Trim and Fill provided insufficient correction when between-study variance exceeded 0.3. No single method is universally best; selection should be guided by heterogeneity magnitude and study count, with multiple methods reported. A key limitation is that only one-sided selection was simulated, excluding outcome reporting bias and p-hacking.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Do Trim and Fill, PET-PEESE, and the Copas selection model perform for correcting publication bias under varying heterogeneity and study counts in meta-analysis? We have simulated 13,480 meta-analyses across 135 scenarios crossing three effect sizes, three heterogeneity levels, three study counts, and five selection mechanisms. Each of these datasets was analysed with unadjusted random-effects, Trim and Fill, PET-PEESE regression, and Copas maximum-likelihood selection modelling, we evaluated by bias, RMSE, and coverage. We found the Copas model achieved the lowest median RMSE across scenarios with twenty or more studies (and maintained 95% CI coverage of 89-96%).PET-PEESE overcorrected under high heterogeneity with coverage below 50%. All methods were unstable with only ten studies; trim and Fill provided insufficient correction when between-study variance exceeded 0.3. No single method is universally best and selection should be guided by heterogeneity magnitude and study count(using multiple methods). A limitation is that only one-sided selection was simulated.
<!-- END-REWRITE -->

_Line range 10369-10443 in rewrite-workbook.txt_

---

## Entry 138 ([142/921]) — PubBiasSuite

<details><summary>Metadata</summary>

```
TITLE: PubBias Suite: Comprehensive Publication Bias Assessment with 12 Methods and 3 Funnel Plot Variants
TYPE: methods  |  ESTIMAND: Bias-adjusted pooled effect estimates
DATA: 12 bias methods + 3 funnel plots
PATH: C:\Models\PubBiasSuite
```

</details>

### Original (frozen — do not edit)

```
How can meta-analysts assess publication bias using multiple complementary methods within a single integrated environment? PubBias Suite runs 12 detection and adjustment methods simultaneously, including Egger regression, Begg rank correlation, trim-and-fill, PET-PEESE, three-parameter selection modeling, p-curve, p-uniform star, WAAP-WLS, and limit meta-analysis, alongside three funnel plot variants. Each method uses the same dataset with traffic-light verdicts indicating whether bias is detected, enabling triangulation across regression tests, selection models, and nonparametric corrections. Validation across 25 Selenium tests confirmed correct execution for all 12 methods and 3 funnel types using the Turner 2008 antidepressant SMD dataset comprising 47 studies with 95% CI validation. Individual implementations were cross-validated against R metafor, meta, and puniform packages with results matching within documented tolerances. The tool enables multi-method assessment reducing reliance on any single diagnostic when evaluating evidence reliability. Most methods have limited power below approximately 10 studies, and results should be interpreted cautiously in small meta-analyses where detection is inherently unreliable.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Can meta-analysts assess publication bias using multiple complementary methods within a single environment? PubBias Suite runs 12 detection and adjustment methods simultaneously, including Egger regression, Begg rank correlation, trim-and-fill, PET-PEESE, three-parameter selection modeling, p-curve, p-uniform star, WAAP-WLS, and limit meta-analysis, alongside three funnel plot variants. Every method uses the same dataset with traffic-light verdicts indicating whether bias is detected, this enables triangulation across regression tests, selection models, and nonparametric corrections. Our Validation across 25 Selenium tests confirmed correct execution for all 12 methods and 3 funnel types using the Turner 2008 antidepressant SMD dataset comprising 47 studies with 95% CI validation. The individual implementations were cross-validated against R metafor, meta, and puniform packages, the results matched within documented tolerances. The tool enables multi-method assessment reduced reliance on any single diagnostic (when evaluating evidence reliability). Most methods have limited power below approximately 10 studies so results should be interpreted cautiously in small meta-analyses.
<!-- END-REWRITE -->

_Line range 10444-10518 in rewrite-workbook.txt_

---

## Entry 139 ([143/921]) — rct-extractor-v2

<details><summary>Metadata</summary>

```
TITLE: Deterministic Effect Estimate Extraction from RCT PDFs
TYPE: methods  |  ESTIMAND: Sensitivity
DATA: 407 published RCT PDFs, 33 ClinicalTrials.gov validated trials
PATH: C:\Projects\rct-extractor-v2
```

</details>

### Original (frozen — do not edit)

```
Can a deterministic regex pipeline extract effect estimates from randomized controlled trial PDFs accurately enough for automated meta-analysis? We applied RCT Extractor v10.3 to 407 published trial PDFs spanning nine effect types including hazard ratios, odds ratios, risk ratios, mean differences, and standardized mean differences. The system chains 180 regex patterns, a finite-state-machine tokenizer, and team-of-rivals consensus voting through pdfplumber, PyMuPDF, table parsing, and OCR with provenance tracking attaching source text and content hash to every extraction. Against ClinicalTrials.gov registry data for 33 validated trials, the pipeline achieved 97.7 percent sensitivity (95% CI 92.0-99.7) for primary endpoint extraction, with 757 pattern-level tests passing across all types. Leave-one-type-out analysis confirmed stable performance across all nine effect measures and multiple publication formats. Deterministic extraction can serve as a scalable first-pass audit layer for systematic reviews requiring rapid effect-size verification from source documents. However, generalizability beyond English-language cardiology-heavy corpora remains a limitation requiring prospective validation on broader clinical domains.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Will a deterministic regex pipeline extract effect estimates from randomized controlled trial PDFs accurately enough for automated meta-analysis? We applied the RCT Extractor v10.3 to 407 published trial PDFs spanning nine effect types including hazard ratios, odds ratios, risk ratios, mean differences, and standardized mean differences. The system brings together 180 regex patterns, a finite-state-machine tokenizer, and team-of-rivals consensus voting through pdfplumber, PyMuPDF, table parsing, and OCR with provenance tracking attaching source text and content hash to every extraction. We used ClinicalTrials.gov registry data for 33 validated trials, the pipeline achieved 97.7 percent sensitivity (95% CI 92.0-99.7) for primary endpoint extraction (with 757 pattern-level tests passing across all types). Leave-one-type-out analysis confirmed stable performance across all nine effect measures in multiple publication formats. Deterministic extraction can serve as a scalable first-pass audit layer for systematic reviews requiring rapid effect-size verification. However, generalizability beyond English-language cardiology-heavy corpora is a limitation requiring prospective validation.
<!-- END-REWRITE -->

_Line range 10519-10593 in rewrite-workbook.txt_

---

## Entry 140 ([144/921]) — reduced-dose-doacs-vte-demo

<details><summary>Metadata</summary>

```
TITLE: Reduced-dose direct oral anticoagulants for extended venous thromboembolism prevention
TYPE: pairwise  |  ESTIMAND: Risk ratio for major bleeding
DATA: Embedded summary rows in this demo JSON
PATH: C:\E156\releases\reduced-dose-doacs-vte-demo
```

</details>

### Original (frozen — do not edit)

```
In adults receiving extended anticoagulation after venous thromboembolism, do reduced-dose direct oral anticoagulants preserve efficacy while lowering bleeding versus full-dose therapy? Three randomized trials with 8,615 participants compared reduced-dose and full-dose direct oral anticoagulants for secondary prevention. Investigators systematically searched major databases through March 20, 2025 and pooled trial outcomes as risk ratios with 95% confidence intervals. Reduced-dose therapy lowered major bleeding, with pooled risk ratio 0.49 and 95% confidence interval 0.29 to 0.81. Clinically relevant nonmajor bleeding and all-cause mortality also favored dose reduction, while recurrent venous thromboembolism, pulmonary embolism outcomes, and deep vein thrombosis recurrence remained statistically similar. These findings support reduced-dose regimens as a reasonable long-term option when bleeding avoidance is a clinical priority after initial treatment in routine practice settings. Confidence is limited by only three trials, sparse fatal event counts, and the need for longer follow-up to confirm durability across patient subgroups and to define which patients can safely de-intensify therapy.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
In adults receiving extended anticoagulation after venous thromboembolism: do reduced-dose direct oral anticoagulants preserve efficacy while lowering bleeding versus full-dose therapy? We looked at three randomized trials with 8,615 participants compared reduced-dose and full-dose direct oral anticoagulants for secondary prevention. Investigators then systematically searched major databases through March 20, 2025 and pooled trial outcomes as risk ratios with 95% confidence intervals. The Reduced-dose therapy lowered major bleeding, with pooled risk ratio 0.49 and 95% confidence interval 0.29 to 0.81. Clinically relevant nonmajor bleeding and all-cause mortality were also favoring dose reduction; recurrent venous thromboembolism, pulmonary embolism outcomes, and deep vein thrombosis recurrence remained statistically similar. These findings suggest reduced-dose regimens as a reasonable long-term option (when bleeding avoidance is a clinical priority) after initial treatment in routine practice settings. Confidence is limited by only three trials, sparse fatal event counts, and the need for longer follow-up.
<!-- END-REWRITE -->

_Line range 10594-10668 in rewrite-workbook.txt_

---

## Entry 141 ([145/921]) — registry_first_rct_meta

<details><summary>Metadata</summary>

```
TITLE: Registry-First Meta-Analysis: Quantifying Missing Cardiovascular Trial Evidence
TYPE: methods  |  ESTIMAND: Evidence Coverage Ratio (trial-level)
DATA: 40 Cochrane cardiovascular review topics linked to ClinicalTrials.gov via API v2, PubMed, and OpenAl
PATH: C:\Projects\registry_first_rct_meta
STATUS NOTE (2026-04-21): OA PDF augmentation is now live for bounded topic runs. A 21-trial empagliflozin sample recovered one publication-verified trial (`NCT04509674`) with direct `RR 0.79 (95% CI 0.63-0.98)` and `HR 0.75 (95% CI 0.57-0.99)`, and the downstream population layer flipped to `effect_available=1.0`; the manuscript body below was not changed.
```

</details>

### Original (frozen — do not edit)

```
How much completed cardiovascular trial evidence registered on ClinicalTrials.gov is missing from published systematic reviews and what are the consequences for pooled estimates? We applied a registry-first framework to 40 Cochrane cardiovascular review topics, building trial universes from registrations and linking publications through identifier and title matching. Evidence Coverage Ratios were computed at trial and participant levels, with missing-not-at-random sensitivity analyses modelling unreported trials under null, attenuated, and adverse assumptions. The median trial-level coverage was 68% (IQR 52-81%) and participant-weighted coverage was 78%, meaning approximately one-third of completed registered trials lacked retrievable published results. Sensitivity analyses shifted pooled estimates by a median of 12% toward the null when assuming missing trials showed no benefit, with worst-case shifts reaching 22%. Registry-first denominator analysis quantifies evidence completeness directly, providing a structural complement to statistical funnel plot asymmetry tests. A limitation is that registry metadata quality varies across periods and areas, and coverage depends on completeness of identifier linking.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
What number of completed cardiovascular trial evidence registered on ClinicalTrials.gov is missing from published systematic reviews. What are the consequences for pooled estimates, and we applied a registry-first framework to 40 Cochrane cardiovascular review topics, we built trial universes from registrations and linking publications through identifier and title matching. Evidence Coverage Ratios were computed at trial and participant levels (with missing-not-at-random sensitivity analyses modelling unreported trials under null, attenuated, and adverse assumptions). The median trial-level coverage was 68% (IQR 52-81%) and participant-weighted coverage was 78%, this means approximately one-third of completed registered trials lacked retrievable published results. Sensitivity analyses shifted pooled estimates by a median of 12% toward the null when assuming missing trials showed no benefit. The worst-case shifts reached 22%; registry-first denominator analysis quantifies evidence completeness directly, this provides a structural complement to statistical funnel plot asymmetry tests. The limitation is that registry metadata quality varies across periods and areas.
<!-- END-REWRITE -->

_Line range 10669-10744 in rewrite-workbook.txt_

---

## Entry 142 ([146/921]) — repo100

<details><summary>Metadata</summary>

```
TITLE: repo100: A Curated Collection of 137 Meta-Regression Benchmark Datasets
TYPE: methods  |  ESTIMAND: Dataset count and median study size
DATA: 137 meta-regression datasets from 70 CRAN packages and 67 GitHub repos
PATH: C:\Projects\repo100
```

</details>

### Original (frozen — do not edit)

```
What characteristics define available meta-regression datasets across medical and social science domains, and how can they serve as methods benchmarks? We curated 137 datasets from 70 CRAN packages and 67 GitHub repositories, standardising each to a common schema with effect sizes, sampling variances, and coded moderators. Each dataset was validated for completeness, deduplicated across sources, and annotated with provenance metadata including study count, effect measure, and moderator inventory. The collection spans 4-2439 studies per dataset with a median of 50 (IQR 20-120), covering odds ratios, standardised mean differences, correlations, and risk ratios across clinical, psychological, and educational domains. All 137 datasets contain at least one coded moderator, with a mean of 13.5 moderators per dataset enabling multivariate regression benchmarking. This open repository provides a ready-made testbed for developing and comparing meta-regression estimation methods against diverse real-world evidence structures. A limitation is that dataset selection reflects R package availability rather than systematic sampling of the meta-analytic literature.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
What characteristics can define available meta-regression datasets across medical and social science domains. How can they serve as methods benchmarks, and we curated 137 datasets from 70 CRAN packages and 67 GitHub repositories, we standardised each to a common schema with effect sizes, sampling variances, and coded moderators. Each dataset was validated for completeness, deduplicated across sources, and annotated with provenance metadata including study count, effect measure, and moderator inventory. This collection spans 4-2439 studies per dataset with a median of 50 (IQR 20-120), it covers odds ratios, standardised mean differences, correlations, and risk ratios across clinical, psychological, and educational domains. All the 137 datasets contain at least one coded moderator (with a mean of 13.5 moderators per dataset enabling multivariate regression benchmarking). This open repository provides a ready-made testbed for developing and comparing meta-regression estimation methods. A limitation is that dataset selection reflects R package availability rather than a systematic sampling of the meta-analytic literature.
<!-- END-REWRITE -->

_Line range 10745-10819 in rewrite-workbook.txt_

---

## Entry 143 ([147/921]) — repo300-ENMA-SNMA

<details><summary>Metadata</summary>

```
TITLE: Ensemble and Spectral Network Meta-Analysis: Novel Inconsistency-Robust Methods
TYPE: methods  |  ESTIMAND: Coverage improvement (percentage points)
DATA: 100 simulation replications x 5 topologies + 3 empirical NMA datasets (smoking, thrombolytics, Parki
PATH: C:\Projects\repo300-ENMA-SNMA
```

</details>

### Original (frozen — do not edit)

```
Can ensemble and spectral approaches improve inconsistency detection and robustness in network meta-analysis compared to standard methods? We developed two novel methods evaluated across 100 simulation replications per scenario using five network topologies with varying heterogeneity and inconsistency, plus three canonical empirical datasets. Ensemble NMA synthesises three complementary inconsistency diagnostics into an Inconsistency Confidence Score per edge and inflates variance adaptively, while Spectral NMA applies graph Laplacian eigen-decomposition to detect inconsistency via high-frequency energy in treatment effect signals. The median coverage improvement for Ensemble NMA was 1.8 percentage points (95% CI 1.5-2.2) across scenarios where inconsistency was present, without increasing RMSE over standard network meta-analysis. Spectral NMA runs in milliseconds versus minutes for MCMC-based diagnostics and correctly identified inconsistent edges in the thrombolytic therapy dataset. These methods offer computationally efficient, complementary tools for assessing and accommodating inconsistency in evidence networks. A limitation is that simulations used normal approximations rather than exact binomial or survival data-generating processes.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Will ensemble and spectral approaches improve inconsistency detection and robustness in network meta-analysis (compared to standard methods)? We developed two novel methods evaluated across 100 simulation replications per scenario using five network topologies, these had varying heterogeneity and inconsistency, we also used three canonical empirical datasets. Ensemble NMA synthesises three complementary inconsistency diagnostics into an Inconsistency Confidence Score per edge and inflates variance adaptively; spectral NMA applies graph Laplacian eigen-decomposition to detect inconsistency via high-frequency energy in treatment effect signals. The median coverage improvement for Ensemble NMA was 1.8 percentage points (95% CI 1.5-2.2) across scenarios where inconsistency was present. Spectral NMA runs in milliseconds versus minutes for MCMC-based diagnostics, it correctly identified inconsistent edges in the thrombolytic therapy dataset. These methods offer computationally efficient, yet complementary tools for assessing and accommodating inconsistency in evidence networks. A limitation is that simulations used normal approximations rather than the exact binomial or survival data-generating processes.
<!-- END-REWRITE -->

_Line range 10820-10894 in rewrite-workbook.txt_

---

## Entry 144 ([148/921]) — RMSTmeta

<details><summary>Metadata</summary>

```
TITLE: RMST Meta: A Browser Tool for Meta-Analysis of Restricted Mean Survival Time Beyond the Hazard Ratio
TYPE: methods  |  ESTIMAND: Pooled RMST difference (months)
DATA: 5 PD-1 inhibitor NSCLC trials (CheckMate-017/057, KEYNOTE-010/024, OAK)
PATH: C:\RMSTmeta
```

</details>

### Original (frozen — do not edit)

```
Can restricted mean survival time differences be pooled across trials in a browser-based meta-analysis tool that avoids the proportional hazards assumption inherently required by standard hazard ratio synthesis? The tool was applied to five landmark PD-1 inhibitor trials for advanced non-small-cell lung cancer totaling over 5000 participants at a 24-month horizon. DerSimonian-Laird random-effects pooling with optional Hartung-Knapp-Sidik-Jonkman adjustment and prediction intervals was implemented in 1224 lines of dependency-free JavaScript. The pooled RMST mean difference was 2.59 months favoring immunotherapy (95% CI 1.94 to 3.23), directly interpretable as additional survival time gained per patient. Leave-one-out sensitivity analysis and funnel plot inspection confirmed stability, with no single trial altering the conclusion and no evidence of asymmetry. RMST meta-analysis provides a clinically intuitive absolute time-scale summary that complements the relative hazard ratio in settings where treatment benefit evolves over time. The tool is limited to pre-computed RMST differences and cannot reconstruct individual patient survival curves from published Kaplan-Meier figures.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Can we used restricted mean survival time differences pooled across trials in a browser-based meta-analysis tool (that avoids the proportional hazards assumption inherently required by standard hazard ratio synthesis)? The tool was applied to five landmark PD-1 inhibitor trials for advanced non-small-cell lung cancer, this over 5000 participants at a 24-month horizon. DerSimonian-Laird random-effects pooling with optional Hartung-Knapp-Sidik-Jonkman adjustment and prediction intervals is implemented in 1224 lines of JavaScript, the pooled RMST mean difference was 2.59 months favoring immunotherapy (95% CI 1.94 to 3.23). This is directly interpretable as additional survival time gained per patient; leave-one-out sensitivity analysis and funnel plot inspection confirmed stability. No single trial altered the conclusion and no evidence of asymmetry; rMST meta-analysis provides a clinically intuitive absolute time-scale summary. It complements the relative hazard ratio in settings where treatment benefit evolves over time. The tool is limited to pre-computed RMST differences (it cannot reconstruct individual patient survival curves from Kaplan-Meier figures).
<!-- END-REWRITE -->

_Line range 10895-10969 in rewrite-workbook.txt_

---

## Entry 145 ([149/921]) — rmstnma

<details><summary>Metadata</summary>

```
TITLE: Bayesian RMST Network Meta-Analysis: The rmstnma R Package
TYPE: methods  |  ESTIMAND: RMST difference (months)
DATA: Illustrative 3-study network with reconstructed Kaplan-Meier data
PATH: C:\Projects\rmstnma
```

</details>

### Original (frozen — do not edit)

```
Can restricted mean survival time replace hazard ratios in network meta-analysis when the proportional hazards assumption is violated? We developed the rmstnma R package implementing a Bayesian network meta-analysis for RMST outcomes, using Stan for posterior inference with Royston-Parmar spline and piecewise constant baseline hazard specifications. The framework propagates Kaplan-Meier reconstruction uncertainty through to treatment rankings, SUCRA scores, and RMST differences at user-specified restriction times. In an illustrative three-study network, the mean difference in RMST between best and worst treatments was 3.8 months (95% credible interval 1.2-6.4), with posterior probability of superiority exceeding 0.90 for the top-ranked treatment. Estimates were sensitive to restriction time choice, with treatment rankings reversing at horizons below 12 months in sensitivity analyses. RMST-based network meta-analysis provides clinically interpretable absolute treatment comparisons without requiring proportional hazards, offering a practical alternative for immuno-oncology settings. A limitation is that the method requires digitised survival curves when individual patient data are unavailable from primary trials.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Will restricted mean survival time replace hazard ratios in network meta-analysis if the proportional hazards assumption fails? We developed rmstnma, an R package implementing Bayesian network meta-analysis for RMST outcomes using Stan with Royston-Parmar spline and piecewise constant baseline hazard models. The framework propagates Kaplan-Meier reconstruction uncertainty through to treatment rankings with model comparison via WAIC and LOO-CV. For a three-study network, the mean RMST difference between best and worst treatments was 3.8 months (95% CrI 1.2 to 6.4) with posterior superiority probability exceeding 0.90 for the top-ranked treatment. Estimates were sensitive to restriction time choice, with treatment rankings reversing at horizons below 12 months in sensitivity analyses. RMST-based network meta-analysis provides clinically interpretable absolute treatment comparisons as a practical alternative for immuno-oncology settings. The method requires digitised survival curves when individual patient data are unavailable, limiting precision.
<!-- END-REWRITE -->

_Line range 10970-11044 in rewrite-workbook.txt_

---

## Entry 146 ([150/921]) — RoBAssessor

<details><summary>Metadata</summary>

```
TITLE: RoB Assessor: A Browser-Based Risk of Bias Assessment Tool Implementing RoB 2 and ROBINS-I
TYPE: methods  |  ESTIMAND: Domain-level and overall risk of bias judgments
DATA: RoB 2 (5 domains) + ROBINS-I (7 domains)
PATH: C:\Models\RoBAssessor
```

</details>

### Original (frozen — do not edit)

```
How can systematic reviewers perform structured risk of bias assessment following Cochrane guidance without proprietary software or manual spreadsheets? RoB Assessor implements the complete RoB 2 framework with five domains for randomized trials alongside the full ROBINS-I framework with seven domains for non-randomized studies, both with algorithm-guided judgment suggestions following Cochrane decision rules. The tool supports mixed-framework assessments within a single project, producing publication-ready traffic light tables and domain-level weighted bar charts with color-coded completion tracking. Across 25 automated Selenium tests, the application achieved 100 percent pass rates for sensitivity checks including domain navigation, judgment propagation, batch import, CI rendering, and export. Domain structures and algorithms were cross-checked against the Cochrane RoB 2 guidance and the ROBINS-I instrument by Sterne and colleagues. The tool provides a transparent, auditable assessment workflow generating manuscript-ready outputs from structured domain-level judgments. Assessment quality depends on reviewer expertise; algorithm-guided suggestions cannot substitute for methodological training or domain knowledge in bias evaluation.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Can systematic reviewers perform structured risk of bias assessment following Cochrane guidance (without proprietary software or manual spreadsheets)? RoB Assessor implements the complete RoB 2 framework with five domains for randomized trials or the full ROBINS-I framework with seven domains for non-randomized studies. This is with with algorithm-guided judgment suggestions following Cochrane decision rules, the tool supports mixed-framework assessments within a single project. It produces publication-ready traffic light tables and domain-level weighted bar charts with color-coded completion tracking. Using 25 automated Selenium tests, the application achieved 100 percent pass rates for sensitivity checks, this included domain navigation, judgment propagation, batch import, CI rendering, and export. Domain structures and algorithms were also cross-checked against the Cochrane RoB 2 guidance and the ROBINS-I instrument by Sterne and colleagues. The tool provides a transparent workflow generating manuscript-ready outputs from structured domain-level judgments; guided suggestions cannot substitute for methodological training or domain knowledge in bias evaluation.
<!-- END-REWRITE -->

_Line range 11045-11119 in rewrite-workbook.txt_

---

## Entry 147 ([151/921]) — ROBMA

<details><summary>Metadata</summary>

```
TITLE: ROBMA Reproducibility Capsule for Reviewer-Auditable Bayesian Model Averaging
TYPE: methods  |  ESTIMAND: summary effect
DATA: Repository artifacts in /mnt/c/Models/ROBMA
PATH: C:\Models\ROBMA
```

</details>

### Original (frozen — do not edit)

```
Can a reproducibility capsule make robust Bayesian model-averaging analyses reviewer-auditable without requiring reimplementation of the statistical engine? We packaged four dose-response studies with 540 participants, a narrated walkthrough, and deterministic validation checksums into a local directory alongside a submission-ready F1000Research manuscript. The capsule bundles fixed inputs, expected outputs, and a rerun script so reviewers can regenerate the validation summary and confirm artifact integrity via inverse-variance checksum pooling. Reviewers who reran the script reproduced the checksum pooled mean difference of 0.134 (SE 0.055, 95% CI 0.026 to 0.242) and the leave-one-out range 0.100 to 0.193 with numerically identical results. All four validation checks passed on independent machines running different Python versions, with zero missing values in the shipped example. The capsule converts opaque claims into a version-pinned audit trail that reviewers can verify within five minutes. This approach addresses packaging only; it does not validate the upstream RoBMA engine, and generalisability beyond the four-study example remains untested.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
With a reproducibility capsule is it possible to make robust Bayesian model-averaging analyses reviewer-auditable without requiring reimplementation of the statistical engine? We looked at four dose-response studies with 540 participants, a narrated walkthrough, and deterministic validation checksums into a local directory. The capsule bundles fixed inputs, expected outputs, and a rerun script so reviewers can regenerate the validation summary and confirm artifact integrity (via inverse-variance checksum pooling). Reviewers who reran the script reproduced the checksum pooled mean difference of 0.134 (SE 0.055, 95% CI 0.026 to 0.242) and the leave-one-out range 0.100 to 0.193 with numerically identical results. All four validation checks passed on machines running different Python versions, there were zero missing values in the shipped example. The capsule converts opaque claims into a version-pinned for reviewers can verify within five minutes. This approach addresses packaging only; it does not validate the upstream RoBMA engine.
<!-- END-REWRITE -->

_Line range 11120-11194 in rewrite-workbook.txt_

---

## Entry 148 ([152/921]) — shahzaib-icu-landscape

<details><summary>Metadata</summary>

```
TITLE: ICU Hemodynamic Trial Landscape: A Living Evidence Map
TYPE: methods  |  ESTIMAND: Sensitivity
DATA: ClinicalTrials.gov ICU RCTs, 21-trial reference standard
PATH: C:\Models\shahzaib-icu-landscape
```

</details>

### Original (frozen — do not edit)

```
Can a browser-based living evidence map provide reviewer-auditable trial landscape coverage for intensive care hemodynamic research? We built a pipeline that fetches ICU randomized controlled trials from ClinicalTrials.gov, enriches records via seven adapters including PubMed, OpenAlex, and FAERS, and renders two interactive dashboards with evidence-gap visualizations and PRISMA-style flow diagrams. The system uses keyword normalization, placebo-arm classification, deduplication validation, and incremental merge logic with a living update log recording every refresh cycle and its provenance metadata. Against a 21-trial reference standard for hemodynamic ICU interventions, the pipeline achieved sensitivity of 100 percent (95% CI 83.9-100) with all trials correctly classified. Stratified keyword-validation samples and deduplication checks confirmed consistent categorization across intervention classes, phases, and enrollment status. The platform serves as a descriptive evidence-mapping tool making registration coverage and signal gaps inspectable without requiring users to engage with code. However, the limitation of registry-only data means that unpublished results and non-registered trials remain invisible to this approach.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Will a browser-based living evidence map provide reviewer-auditable trial landscape coverage for intensive care hemodynamic research? We built a pipeline that fetches ICU randomized controlled trials from ClinicalTrials.gov, enriches records via seven adapters including PubMed, OpenAlex, and FAERS, and renders two interactive dashboards with evidence-gap visualizations and PRISMA-style flow diagrams. The system uses keyword normalization, placebo-arm classification, deduplication validation, and incremental merge logic with a living update log recording every refresh cycle. Against a 21-trial reference standard for hemodynamic ICU interventions, the pipeline achieved sensitivity of 100 percent (95% CI 83.9 to 100) with all trials correctly classified. Stratified keyword-validation samples and deduplication checks confirmed consistent categorization across intervention classes, phases, and enrollment status. The platform serves as an evidence-mapping tool making registration coverage and signal gaps inspectable without code. Registry-only data means that unpublished results and non-registered trials remain invisible.
<!-- END-REWRITE -->

_Line range 11195-11269 in rewrite-workbook.txt_

---

## Entry 149 ([153/921]) — SheafNMA

<details><summary>Metadata</summary>

```
TITLE: Sheaf-Theoretic Consistency Analysis for Network Meta-Analysis
TYPE: methods  |  ESTIMAND: Global Inconsistency Index (GII)
DATA: Contrast-level NMA data with treatment labels and standard errors
PATH: C:\Models\SheafNMA
```

</details>

### Original (frozen — do not edit)

```
Can treating NMA contrasts as algebraic graph sections yield a global inconsistency statistic and per-edge localization from one object? We applied cellular-sheaf theory to thirteen published Cochrane and textbook NMAs from the R netmeta package, spanning diabetes, thrombolytics, acupuncture, and antimanic agents. The engine builds a precision-weighted coboundary operator and sheaf Laplacian, solves a weighted least-squares system, and reports the Global Inconsistency Index and per-edge residual scores. Sheaf-residual flagging identified localized inconsistency in five of thirteen NMAs where the design-by-treatment chi-squared failed to reject at 0.05, indicating 38.5 percent of apparently-consistent networks harbored at least one inconsistent edge. Across a 36-cell simulation grid with one thousand replications, Type-I error averaged zero and sensitivity reached 0.981 at planted-inconsistency magnitude 0.5. Per-edge agreement with node-splitting was 45.4 percent, reflecting a deliberately conservative Youden-optimal threshold of 2.69. Sheaf analysis emits global and local diagnostics from one algebraic object, complementing node-splitting, though single-dimensional stalks do not yet handle multi-arm covariance.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Can we detect and localize inconsistency in network meta-analysis using algebraic methods (beyond the traditional loop-based splitting approach)? We applied sheaf theory to network meta-analysis, we modeled treatment contrasts as sections over a graph where edges carry precision-weighted comparisons, the engine constructs a coboundary operator. It assembles the sheaf Laplacian matrix and computes eigenvalues to derive a global inconsistency index, it assigns per-edge residual scores with network visualization. On a smoking cessation network with 24 contrasts, the global inconsistency index was 3.41 (95% CI 1.87 to 5.12 via bootstrap).The self-help edge contributed 62 percent of inconsistency. Removing that edge reduced the global index to 1.28, this confirmed localized rather than diffuse inconsistency in the network. Sheaf-theoretic analysis thus complements node-splitting by providing simultaneous global and local diagnostics within a unified algebraic framework (applicable to any connected evidence network). One limitation is that the method assumes normally distributed contrast estimates and cannot accommodate multi-arm covariance corrections.
<!-- END-REWRITE -->

_Line range 11270-11344 in rewrite-workbook.txt_

---

## Entry 150 ([154/921]) — SoFTable

<details><summary>Metadata</summary>

```
TITLE: GRADE Summary of Findings Table Generator for Systematic Reviews
TYPE: methods  |  ESTIMAND: GRADE certainty rating
DATA: User-entered outcome-level summary data with GRADE domain judgments
PATH: C:\Models\SoFTable
```

</details>

### Original (frozen — do not edit)

```
How can systematic reviewers generate GRADE-compliant Summary of Findings tables with automatic certainty assessment without proprietary desktop software? We developed a browser tool implementing the GRADE framework for rating certainty across five downgrading and three upgrading domains with real-time effect computation. The application accepts outcome data including effect measures, confidence intervals, baseline risks, and domain judgments, then computes certainty ratings and generates formatted tables with plain-language statements. The tool matched expert GRADE certainty ratings in 5 of 6 demonstration outcomes (83 percent agreement, 95% CI 36 to 100) within one level for all six cases tested. Toggling individual domain judgments instantly updates the composite rating and recalculates absolute effects, enabling transparent sensitivity exploration for each downgrading decision. The generator standardizes GRADE implementation for teams lacking access to commercial software while maintaining export compatibility with common formats. One limitation is that the imprecision judgment uses simplified optimal information size thresholds rather than fully contextualized clinical decision boundaries.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Can systematic reviewers generate GRADE-compliant Summary of Findings tables with automatic certainty assessment without desktop software? We developed a browser tool for implementing the GRADE framework for rating certainty across five downgrading and three upgrading domains with real-time effect computation. The application uses outcome data including effect measures, confidence intervals, baseline risks, and domain judgments, it then computes certainty ratings and generates formatted tables with plain-language statements. The tool matched expert GRADE certainty ratings in 5 of 6 demonstration outcomes (83 percent agreement, 95% CI 36 to 100) within one level for all six cases tested. Using Toggling individual domain judgments instantly updates the composite rating and recalculates absolute effects. This enables transparent sensitivity exploration for each downgrading decision, the generator standardizes GRADE implementation for teams lacking access to commercial software. One limitation is that the imprecision judgment uses simplified optimal information size thresholds.
<!-- END-REWRITE -->

_Line range 11345-11419 in rewrite-workbook.txt_

---

